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ACE Angiotensin-converting-enzyme 
 
ADRB2 Adrenergic beta receptor – 2 
 
ALP Alkaline phosphatase 
 
BGLAP Bone gamma carboxyglutamic acid-containing protein 
 
BMP-2 Bone morphogenic protein – 2 
 
cAMP cyclic Adenosine Monophosphate 
 
CGRP Calcitonin gene-related peptide 
 
CHRM2 Cholinergic muscarinic receptor – 2 
 
CNS Central nervous system 
 
Col-1 Collagen – 1 
 
CRP C-reactive protein 
 
CRPS Complex regional pain syndrome 
 
DFNS Deutschen Forschungsverbund Neuropathischer Schmerz 
 
DKK1 Dickkopf – 1 
 
DRG Dorsal root ganglion 
 
ELISA Enzyme linked immunosorbent assay 
 
FACS Fluorescence activated cell sorting 
 
FBS Fetal bovine serum 
 
GPCR G-protein coupled receptors 
 
HC Healthy control 
 
HCMEC Human cerebral microvascular endothelial cells 
 
HLA Human leukocyte antigen 
 
IASP International Association for the Study of Pain 
 
ICAM-1 Intercellular adhesion molecule – 1 
 
IFN Interferon 
 
IgG Immunoglobulin G 
 
IL-1 Interleukin – 1 beta 
 
IL-6 Interleukin – 6 
 
IvIg Intravenous immunoglobulin 
 
LDH Lactate dehydrogenase 
 
MCP-1 Monocyte chemoattractant protein – 1 
 
MFI Mean fluorescence intensity 
 
MSC Mesenchymal stem cells 
 
NGF Nerve growth factor 
 
NK1 Neurokinin-1 
 
NMDA N-methyl-D-aspartate 
 
NSAIDs Non-steroidal anti-inflammatory drugs 
 
OPN Osteopontin 
 
PET Positron emission tomography 
 
PKA Protein kinase - A 
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PNS Peripheral nervous system 
 
QST Quantitative sensory testing 
 
RA Rheumatoid arthritis 
 
RF Radial fracture 
 
RSD Reflex sympathetic dystrophy 
 
SLE Systemic lupus erythmatosus 
 
SMP Sympathetically maintained pain 
 
SP Substance P 
 
SPECT Single photon emission computed tomography 
 
SS Sjögren’s syndrome 
 
TGF-1 Transforming growth factor beta-1 
 
TLR Toll-like receptor 
 
TNF- Tumor necrosis factor alpha 
 
TRPV1 Transient receptor potential vanilloid receptor – 1 
 
VCAM-1 Vascular cell adhesion molecule – 1 
 
VGKC Voltage gated potassium channels 
 
ZK Zellen von Knochen (Bone cell) 
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Figure 1A: Acute CRPS, chronic CRPS, and CRPS dystonia. 
 
Figure 1B: Possible mechanism for development of RSD / CRPS. 
 
Figure 2: Role of heterotrimeric G proteins in mediating autonomic control by sympathetic 
and parasympathetic system. 
 
Figure 3: Possible mechanism of action and potential autoantibody binding sites in CRPS 
patients for Beta-2-adrenergic (2AR) and Muscarinic-2 acetylcholine 
receptor M2R autoantibodies. 
 
Figure 4: Model of regulation of 2AR signaling by OPN in osteoblasts. 
 
Figure 5: Expression of ADRB2 and CHRM2 receptors in CHO (WT), h2AR-CHO, 
hCHRM2-CHO, HCMEC, HEK293 and A10 cells. 
 
Figure 6: Determination of surface binding of healthy control (HC), CRPS and RF IgG to 
CHO cells overexpressing ADRB2 and CHRM2 receptors by flow cytometry. 
 
Figure 7: h2AR-CHO and hM2R-CHO cells pre-incubated with h2AR with AR 
antagonists significantly reduced the surface binding of autoantibodies. 
 
Figure 8: Binding of functionally active autoantibodies against ADRB2 and CHRM2 
receptors to HCMEC, HEK293 with and without knockdown of CHRM2 
receptor, A10 and SAOS-2 cells. 
 
Figure 9: CRPS IgG mediated cytotoxicity in HCMEC, HEK293, A10 and SAOS-2 cells. 
 
 
Figure 10: CRPS IgG mediated proliferation effects in endothelial, smooth muscle, SAOS-2 
and HEK293 cells. 
 
Figure 11: Antagonizing effects of CRPS IgG by pre-incubating the HCMEC cells with AR 
and M2R antagonists. 
 
Figure 12: Expression of endothelial specific pro-inflammatory cytokines and differentiation 
related genes in HCMEC cells. 
 
Figure 13: CRPS IgG are potent stimulators of ERK 1/2 pathway in HCMEC cells. 
 
Figure 14: CRPS IgG are effective activators of phospho P38 MAPK pathway proteins in 
HCMEC endothelial cells. 
 
Figure 15: CRPS IgG are effective activators of pSTAT-1 (a pro-inflammatory mediating 
protein) in HCMEC cells. 
 
Figure 16: CRPS IgG are effective activators of pAKT (cell differentiation and survival 
mediator) in HCMEC cells. 
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Figure 17: Determination of surface binding autoantibodies in primary osteoblasts 
differentiated from mesenchymal stem cells (MSCs). 
 
Figure 18: Cytotoxicity assay of primary osteoblasts after incubating different IgG for 24hrs. 
 
 
Figure 19: Proliferation assay in primary osteoblasts. 
 
Figure 20: Annexin-V FLUOS immunofluorescence staining to identify apoptotic and 
necrotic osteoblasts after treatment with different IgG. 
 
Figure 21: Relative mRNA expression of osteoblast specific markers in ZK37 primary 
osteoblast. 
 
Figure 22: Relative mRNA expression of osteoblast specific markers in ZK48 primary 
osteoblast. 
 
Figure 23: Relative mRNA expression of osteoblast specific markers in ZK58 primary 
osteoblast. 
 
Figure 24: Immunoblotting of Collagen-1 in ZK37. 
 
Figure 25: IvIg mediated cytotoxic effects of HC, CRPS and CRPS + IvIg to human 
microvascular endothelial cells HCMEC, HEK293 and A10 cells. 
 
Figure 26: IvIg mediated proliferation rate of HCMEC, HEK293 and A10 cells. 
 
Figure 27: Pictorial representation of findings originated from this thesis. 
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Table 1: IASP Diagnostic Criteria For CRPS 
 
Table 2: The Modified Harden/Bruehl Criteria Or “The Budapest Criteria” 
 
Table 3: Clinical and Epidemiological Data of CRPS Patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6,,,
"
 
 
#$!%
 
 
#$#$%&''(&)"*
 
1.1.1. Definition 
 
 
 
Complex regional pain syndrome (CRPS) formerly known as Sudeck’s dystrophy, is a 
chronic neuropathic condition characterized by spontaneous or stimulus induced pain, 
swelling, skin color and temperature changes, vasomotor and sudomotor abnormality 
(sympathetic dysfunction), and impairment of motor function (weakness, tremor, and muscle 
spasms)(de Mos et al., 2009d). The disorder usually is a painful disabling condition in the 
distal limb and develops after minor trauma (contusions, sprain, and minor fractures) or 
surgery and rarely after spinal cord injury, cerebrovascular accidents and cardiac ischaemia 
(Mitchell et al., 2007b; Swart et al., 2009). Fractures are the most common precipitating 
events involving the upper extremity more frequently than the lower (Nishida et al., 2009). 
During cast immobilization, increased pressure and early complaints of tightness are 
predictive factors for the onset of CRPS (Albazaz et al., 2008). In some cases no clear 
eliciting event can be identified. The spontaneous pain (skin, subcutaneous tissue, and joints) 
or hyperalgesia has no correlation to the severity of the trauma and is not limited to the area 
of the trauma. 
 
 
1.1.2 Historical background 
 
 
 
Initial description about the symptoms relating CRPS probably dates back to 1864, when 
Silas Weir Mitchell observed a puzzling collection of symptoms in soldiers with injuries of 
peripheral nerves like constant burning pain in combination with substantial trophic changes. 
 
Mitchell named this syndrome “Causalgia” derived from Greek words ‘burning’ (‘NDQVLV’ 
– kausis) and ‘pain’ (‘DOJRV’ – algos) (Mitchell et al., 2007b). During the First World War, 
Rene Leriche successfully treated such syndromes by surgical sympathectomy. This is where 
the surgeon has presumed the involvement of sympathetic nervous system in this disabling 
and distressing painful condition. John Bonica (who later founded the International 
Association for the Study of Pain; IASP) during the 1950s, developed few invasive 
techniques allowing temporary blockade of the sympathetic nervous system. Through the 
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efficacy followed by these techniques, Evans coined a new term for this condition, which is 
known as ‘Reflex Sympathetic Dystrophy’ (Evans, 1946). At the 24th meeting of the German 
Society of Surgery, surgeon Paul Sudeck in the year 1864 (Mitchell et al., 1864) gave a 
lecture on patients with acute inflammatory bone atrophy. Sudeck mentioned certain key 
symptoms about this syndrome accompanied by inflammation and symptoms might spread 
beyond the region of initial damage (Mitchell et al., 2007a; Sudeck, 2005). It is to honor his 
effort, clinically traumatologists temporarily called this disease as Sudeck’s dystrophy. The 
pathogenicity of this pain syndrome is not yet clear but later there was growing evidence for 
an inflammatory as well as for a sympathetic pathogenesis. Finally, the term RSD was 
abandoned at a consensus conference held in Orlando, Florida, in 1993 and they formulated a 
strictly descriptive term called Complex Regional Pain Syndrome (CRPS) and till date this is 
the official term in the IASP (Stanton-Hicks et al., 1995). 
 
 
1.1.3 Diagnostic criteria 
 
 
 
CRPS is further subdivided into two types: CRPS type I, formerly known as ‘‘reflex 
sympathetic dystrophy’’ (as recommended in 1994 by the International Association for the 
Study of Pain), and CRPS type II, the new term for ‘‘causalgia’’ that always coexists with a 
documented nerve injury (lesion or tumour). In most cases the upper or lower limb is 
affected, but also other body parts or different body parts can be involved at the same time 
(Swart et al., 2009). There were many diagnostic criteria formulated to diagnose the disease 
condition (van de Beek et al., 2002). To address the problems, the IASP proposed a new 
diagnostic criterion (Table 1) in which the clinical symptoms were listed out including 
involvement of sympathetic hyperactivity, allodynia and hyperalgesia (Stanton-Hicks et al., 
1995). Though the IASP diagnostic criteria explained a new taxonomy it failed to formulate 
the specificity and internal validity. Most importantly diagnostic criteria should be able to 
describe a sample and also differentiate it from other patient groups (Bruehl et al., 1999; 
Harden et al., 1999; Perez et al., 2007). In order to address these variable groups, Bruehl and 
Harden came up with new criteria, which is commonly denoted as Harden/Bruehl criteria, or 
The Budapest research criteria (Harden et al., 2007; Harden and Bruehl, 2006). Based on 
these criteria, the patients will be diagnosed by the physician with CRPS if they fulfill atleast 
2 of the 4 categories (Table 2). 
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Table 1: IASP Diagnostic criteria for CRPS (Merskey et al., 1994) 
 
CRPS type I 
 
1. Continuing pain, allodynia or hyperalgesia, edema, changes in skin color, skin blood 
flow and abnormal sudomotor activity in the pain region 
2. Excluded diagnosis that would otherwise account for the degree of pain and 
dysfunction 
 
CRPS type II 
 
1. Syndrome develops after nerve injury. 
 
2. Spontaneous pain or allodynia / hyperalgesia (not limited to the territory of the injured 
nerve) 
 
3. Evidence of edema, abnormalities in skin blood flow and sudomotor activity in the 
region of pain since the inciting event. 
4. Excluded diagnosis that would otherwise account for the degree of pain and 
dysfunction 
 
Table 2: The modified Harden/Bruehl criteria or “The Budapest criteria” (Harden et al., 
2007) 
 
For clinical diagnosis, the following criteria must be met 
 
1. Continuing pain, which is disproportionate to any inciting event 
 
2. Must report at least one symptom in three of the four following categories, Fig 1A. 
Sensory: reports of hypaesthesia and/or allodynia 
Vasomotor: reports of temperature asymmetry and/or skin color changes and/or skin 
color asymmetry 
Sudomotor/edema: reports of edema and/or sweating changes and/or sweating 
asymmetry 
Motor/trophic: reports of decreased range of motion and/or motor dysfunction 
(weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin) 
3. Must display at least one sign at time of evaluation in two or more of the following 
categories 
Sensory: evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch and/or 
temperature sensation and/or deep somatic pressure and/or joint movement) 
 
Vasomotor: evidence of temperature asymmetry (>1°C) and/or skin color changes and/or 
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asymmetry. 
 
Sudomotor/edema: evidence of edema and/or sweating changes and/or sweating 
asymmetry Motor/trophic: evidence of decreased range of motion and/or motor 
dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin) 
 
4. There is no other diagnosis that better explains the signs and symptoms 
 
 
For research purposes, diagnostic decision rule should be at least one symptom in all four 
categories and at least one sign (observed at evaluation) in two or more sign categories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1A: Acute CRPS, chronic CRPS, and CRPS dystonia (A) Acute CRPS with hyperaemia, 
swelling, and glossy skin. (B) Chronic, cold-type CRPS with blue discoloration of the fingers, 
glossy skin, and increased hair and nail growth. (C) CRPS-related dystonia of the left ankle and 
foot with plantar flexion and inversion of the ankle, and flexion of the toes; oedema and increased 
hair growth are also visible. CRPS=complex regional pain syndrome. Source: www.thelancet.com 
 
1.1.4 Epidemiology 
 
 
 
Overall epidemiological screenings were not yet done for CRPS but few studies support the 
upper limbs are twice as frequently affected as the lower limbs (de Mos et al., 2008; Geertzen 
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et al., 1998). The epidemiological data of Olmsted County, Minnesota (North America) 
calculated an incidence rate of 5.46/100,000/year and a prevalence rate of 20.57/100,000 
(Sandroni et al., 2003). In the Netherlands, it was found that each year about 26 out of 
100,000 people develop CRPS (95% CI: 23.0–29.7). This counts to 4300 new sufferers every 
year. Its onset ranges from childhood through old age, but most cases were seen between the 
ages of 50 and 70 years. It is generally believed that CRPS occurs mainly in Caucasian and 
Japanese people (Allen et al., 1999; de Mos et al., 2009d). Prevalence of CRPS following 
fractures is between 0.03% and 37% (Atkins et al., 1989, 1990; Bickerstaff and Kanis, 1994; 
Dijkstra et al., 2003; Field et al., 1992; Raja and Grabow, 2002; Sarangi et al., 1993). 
Generally females are affected more frequent than males with a ratio approximating 3.5 
(Allen et al., 1999; Sumitani et al., 2013). Overall female to male ratio is 2-3:1 and 
postmenopausal women appeared to be more prevalent to develop CRPS. Most of the 
patients experienced preceding trauma, in about 40% of the cases fracture or surgery 
(Beerthuizen et al., 2012). Remarkably, the severity of trauma and degree of CRPS symptoms 
has no distinct correlation (Stanton-Hicks et al., 1995). CRPS may develop at any age but is 
very uncommon in children. The age groups with the highest incidence were observed in 
patients travelling through the 4th to 7th decade of their life (Schwartzman et al., 2009b). 
Although CRPS seems to occur mainly in adults, the syndrome may also develop in children, 
where the skin temperature of the involved extremity at onset was more often cooler, the 
lower limb more frequently affected, and neurological and sympathetic symptoms less 
pronounced. The approximate amount of pediatric patients is less than <10% of all CRPS 
patients (Subbarao and Stillwell, 1981; Tan et al., 2008). 
 
 
 
1.1.5 Etiology 
 
 
 
The main cause or the initial event that leads to this chronic painful condition is not yet 
known. As known so far, CRPS is a multi-faceted disease and previous studies states that 
CRPS should be understood as a biopsychosocial disorder, whereby psychological, 
behavioural, and pathophysiological factors interact in a complex manner (Bruehl and Chung, 
2006). Distal radius fracture is the most common fracture type but only few of those patients 
develop CRPS. There is also evidence for familial occurrence of CRPS (de Rooij et al., 
2009). Neurogenic vasodilation is more intensive in CRPS patients than in healthy 
individuals (Leis et al., 2004). The role of psychological factors, e.g. critical life events or 
 
"
"
 
inadequate coping strategies (i.e. difficulties in dealing with post-trauma consequences) in the 
development or aggravation of CRPS is controversially discussed. Stressful life events in 
approximately 80% of patients suffering from CRPS of the upper limb 2 months before or 1 
month after the development of CRPS, compared with 20% in a control group were observed 
(Geertzen et al., 1998). This suggests a predisposition for neurogenic inflammation in CRPS. 
However, no correlation has been proved so far between the manifestation of CRPS and the 
polymorphisms in genes encoding for ACE (angiotensin-converting enzyme), a 
neuropeptide-degrading enzyme (Huhne et al., 2004). 
 
CRPS varies from mild and self-limiting to a chronic disease with a high impact on daily 
functioning and quality of life (Galer et al., 2000). Chronic patients then experience long-
term suffering (Brunner et al., 2008; de Mos et al., 2009d). The syndrome frequently 
interferes with the ability to work (approximately 62% disability rate), sleep (approximately 
96%), mobility (approximately 86%), and self-care (approximately 57%) (Brunner et al., 
2008; de Mos et al., 2009d). Remissions and relapses are common. Duman et al., reported 
that in Turkey almost one-third of patients with CRPS do not return to work (Duman et al., 
2007). To obtain a good outcome, early recognition and a multidisciplinary approach to 
management seems important (Albazaz et al., 2008). 
 
 
1.1.6 Clinical Manifestation 
 
 
 
The symptoms and clinical presentation are multi-dimensional but studies revealed some 
characteristic features. A striking symptom of CRPS is the presence of distal edema (Fig. 
1B). Incidence of skin temperature changes at the affected body part is 80% (Birklein et al., 
2000). Most of the studies consider a temperature difference of >1°C to be significant. The 
affected limb is initially warm however it becomes colder in the course of disease (Veldman 
et al., 1993). The skin temperature decreases over the course of time. The skin color looks red 
often in the initial stage but turns either pale or livid in chronic stages. 
 
Fifty-five percent of patients with CRPS presented altered sweating of the affected limb with 
hyperhidrosis rather than hypohidrosis (Birklein et al., 1997). Autonomic disturbances 
include atrophy of muscles and bones. Most of the patients develop patchy osteoporosis or 
osteopenia (de Boer et al., 2011; Gierthmuhlen et al., 2012; Sethna et al., 2007). Tropic 
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changes also include thin and shiny skin, increased hair and nail growth with the nails often 
brittle, ridged, curved or dull. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1B: A possible mechanism of development of RSD / 
 
CRPS. Source: International research Foundation for RSD / 
 
CRPS 
 
 
 
 
1.1.6.1. Sensory disturbances 
 
 
 
Sensory disturbances were found in almost 90% of CRPS patients (Birklein et al., 2000; 
Veldman et al., 1993). The major characteristic of pain in CRPS is not limited to the 
innervated territory of a single peripheral nerve. The pain can be spontaneous, continuous and 
episodic in response to physical, noxious or even emotional stimuli (Maihofner et al., 2005; 
Sieweke et al., 1999). Sensory disturbances are often observed in glove or stocking-like 
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pattern. Many patients suffer from hyperalgesia and/or allodynia. Adults with CRPS I and 
 
CRPS II display symptoms like ‘sensory gain’ and ‘sensory loss’ (hypalgesia or 
hypaesthesia) (Gierthmuhlen et al., 2012). In many cases the pain is more pronounced during 
night. Spontaneous pain can be evoked by anxiety, exercise, temperature changes and touch 
even with a light brush. Mostly patients describe the pain as burning, dragging, shooting or 
stinging (Hassantash et al., 2003; Roganovic and Mandic-Gajic, 2006). Patients with CRPS 
also display other sensory abnormalities such as allochiria (unilateral tactile stimuli perceived 
only in the analogous location on the opposite extremity), sensory extinction (bilateral tactile 
stimuli is perceived in both the limbs) (Acerra and Moseley, 2005; Cohen et al., 2013), 
dysynchiria (perceiving pain when watching the mirror image of the unaffected limb being 
stimulated by light touch or pressure so as the affected limb), synchiria (perception of pain to 
a cold stimulus in both affected and unaffected limb) (Acerra and Moseley, 2005) and referral 
sensations (referral of somatosensory feelings to areas that are adjacent of cortical map or 
mislocalization of tactile stimuli) . 
 
 
1.1.6.2. Motor dysfunction 
 
 
 
The majority of patients with CRPS have repeatedly reported motor disturbances such as 
weakness or limited active range of motion (Forderreuther et al., 2004; Schwartzman and 
Kerrigan, 1990). Patients often suffer from muscle spasms, myoclonus and dystonia. In many 
cases the tendon reflexes are exaggerated but in few cases they are diminished (Birklein et 
al., 2000; Forderreuther et al., 2004; Roganovic and Mandic-Gajic, 2006). 
 
Besides that patients couldn’t move their affected extremity, especially complex movements 
like finger-tapping are severely impaired (Birklein et al., 2000). Some studies have reported 
neglect-like symptoms (Galer et al., 1995; Galer and Jensen, 1999). Interestingly, some 
studies claim that patients have varying symptoms such as myoclonic jerks, dystonic muscle 
contractions, neglect-like symptoms (van der Laan et al., 1998). Few recent studies show that 
in pediatric CRPS patients also showed a similar pattern of abnormal movements (Agrawal et 
al., 2009). Moreover, three distinct subtypes or sequential stages were seen in RSD/CRPS. 
They are a) acute phase where the pain, sensory abnormalities, sudomotor functions are 
predominate, b) dystrophic phase where the pain and sensory dysfunction become more 
marked, vasomotor abnormalities persist and significant motor and trophic changes develop 
and c) an atrophic phase where pain and sensory abnormalities decrease, vasomotor and 
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trophic changes increase (Bruehl, 2009; Bruehl et al., 2002; de Mos et al., 2009b; Perez et al., 
2007). 
 
 
1.1.7. Pathophysiological Mechanisms 
 
 
 
CRPS is a disorder with varying clinical symptoms and disease severity. Many factors were 
thought to contribute to CRPS. The major factors include: 
 
I. Neurogenic inflammation, central sensitization and neuropeptides in pain 
 
II. Sympathetic–afferent coupling 
 
III. Hypoxia and free radical formation 
 
IV. Cortical re-organization 
 
V. Immunological disturbances 
 
VI. Genetic predisposition 
 
 
 
1.1.7.1. Neurogenic Inflammation and central sensitization 
 
 
 
CRPS patients exhibit all signs of inflammation such as swelling, pain, redness, infiltrate in 
joint, muscle, skin and heat. Systemic inflammation seems to be more pertinent in CRPS 
rather than local inflammatory responses. Neurogenic inflammation regularly accompanies 
excitation of primary afferent nociceptors causing plasma extravasation and vasodilatation. 
Compared to controls bradykinin was four times higher in venous blood of CRPS patients 
(Albazaz et al., 2008; de Mos et al., 2009d; Nishida et al., 2009). Few studies detected 
Langerhans cells and infiltration of lymphocytes in skin biopsies (Calder et al., 1998; Kozin 
et al., 1976). ACE inhibitors are shown to influence the neuroinflammatory mechanisms in 
CRPS by their interaction with the catabolism of SP and bradykinin (de Mos et al., 2009a). 
 
The increase in serum/plasma CGRP was associated with acetylcholine-induced sweating in 
CRPS patients (Schlereth et al., 2006). Apart from this, the role of CGRP and SP in 
neurogenic inflammation has been investigated in rat tibial fracture casting model (Guo et al., 
2004). At the time of cast removal, upregulation of SP, CGRP and expression of other 
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neuropeptides was detected in skin, sciatic nerve and in DRG (Blair et al., 1998; Weber et al., 
2001; Wei et al., 2009). After tibia fracture, the SP-induced protein extravasation was 
primarily due to the SP-receptor or the neurokinin-1 (NK1) receptor on endothelial cells and 
keratinocytes, whereas decreased enzymatic degradation of SP did not make a major 
contribution (Kingery et al., 2003; Wei et al., 2009). SP was also shown to play a major role 
in activation and proliferation of keratinocytes thereby causing epidermal thickening in rat 
tibia fracture cast model (Wei et al., 2012). Skin biopsy sample from CRPS I patient also 
showed a similar pattern of epidermal thickening and elevated levels of NK1 receptor 
expression on keratinocytes (Kingery, 2010). 
 
Calcitonin gene-related peptide (CGRP) and substance P (SP) are considered to be the most 
important inflammatory mediators. Both SP and CGRP are systemically elevated in CRPS 
patients, which is mainly responsible for vasodilation and protein extravasation respectively. 
Substance P and CGRP do not directly participate in the pain events. Nevertheless, according 
to the tibia fracture model of CRPS I (Guo et al., 2004; Guo et al., 2012; Wei et al., 2012; 
Wei et al., 2009) and sciatic nerve transsection model of CRPS II (Kingery et al., 2003), they 
play a role in spontaneous pain behavior and nociceptor sensitization. A network of 
inflammatory mediators acts together and heightens the pain responses. Those include 
interleukin (IL)-1, IL-6, IL-8, tumor necrosis factor (TNF)- D and nerve growth factor 
(NGF) (Guo et al., 2012; Li et al., 2010; Li et al., 2009a; Li et al., 2009b; Sabsovich et al., 
2008a; Sabsovich et al., 2008b). These agents can further upregulate the neuropeptide 
production resulting in additional inflammation and nociceptive sensitization. Additionally, 
skin mast cells produces other mediators such as tryptase and other proteases, histamine, 
prostaglandins, cytokines and neuropeptides (Leung and Cahill, 2010; Lewin and Mendell, 
1993; Schafers and Sorkin, 2008). Amputated-limb CRPS patients have confirmed the 
presence of nerve degeneration and evidence of vascular inflammation (Coderre and Bennett, 
2008). Continuous nociceptive input, nerve injury, and primary afferent depolarization induce 
neuropeptide release within the dorsal horn, where they can mediate central sensitization 
through interaction with Neurokinin 1 (NK-1) and N-methyl-D-aspartate (NMDA) receptors 
(de Mos et al., 2009d; Latremoliere and Woolf, 2009; Seybold, 2009). In long-standing 
CRPS, there is significant posterior horn cell loss and activation of both microglia and 
astrocytes most prominently at the corresponding level of the original injury (Del Valle et al., 
2009). Spinal neuronal sensitization comprises a state of hyperexcitability and disinhibition, 
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causing a decreased stimulation threshold. Eventually, normally non-painful stimuli become 
painful (de Mos et al., 2009d). 
 
 
1.1.7.2. Sympathetic–afferent coupling 
 
 
The central nervous system interacts with the peripheral system via neural and chemical 
channels and has direct control over the autonomic system, thereby giving rise to the clinical 
irregularity of peripheral vasomotor and sudomotor changes without peripheral neural 
damage. Impaired balance exists in CRPS-affected limbs between vascular regulation 
systems responsible for vasoconstriction and vasodilation (Dayan et al., 2008). The results of 
sympathetic or autonomic hyperactivity are increased sweating, trophic changes, and 
vasoconstriction- related coldness of the affected limb. In Sympathetically Maintained Pain 
(SMP), painful sensations are provoked by sympathetic outflow through sympathetic– 
afferent coupling in which adrenergic receptors are expressed on primary afferent nerve 
endings. Increased sympathetic outflow (hyperactivity) may be one mechanism, whilst 
abnormal sensitivity of adrenergic receptors for normal sympathetic outflow may be another 
(de Mos et al., 2009d). 
 
The sympathetic skin reflexes in CRPS patients are increased. The underlying cause may be 
sprouting of new sympathetic nerves centrally in the dorsal horn or peripherally in the upper 
dermis (de Mos et al., 2009d). The density of D-adrenoreceptors is enlarged in hyperalgesic 
skin from CRPS-affected limbs, while the sympathetic innervation of sweat glands and 
vasculature is abnormal (Albrecht et al., 2006). In contrast, temporarily diminished 
sympathetic stimulation has been suggested as an underlying cause of the adrenergic receptor 
upregulation and sensitization in CRPS patients (de Mos et al., 2009d). Sweating and trophic 
disturbances are not the most predominant features of CRPS but can also be explained as 
neuropeptide effects. Hence, SMP and sympathetic dysregulation can be a part of the CRPS 
symptom complex (de Mos et al., 2009d). 
 
 
1.1.7.3. Hypoxia and free radical formation 
 
 
 
Free radicals are involved in the pathophysiology of CRPS-I. Presence of hypoxia in CRPS is 
endorsed by several observations (de Mos et al., 2009d). Extreme vasoconstriction was 
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thought to cause it, either resulting from a local imbalance between endothelial factors, or 
sympathetically thriven (Schattschneider et al., 2006). Impaired nutritive blood flow could be 
a reason for sympathetic dysfunction and causes hypoxia. The actual presence of local 
hypoxia leading to reactive oxygen species formation (known enhancers of pain and of 
neuroinflammatory responses) has been demonstrated in clinical studies in CRPS patients (de 
Mos et al., 2009c). Higher amounts of malondialdehyde, lactic dehydrogenase, and cellular 
antioxidants (peroxidase, superoxide dismutase, and uric acid) are present in the serum, and 
especially in the saliva (Coderre and Bennett, 2008). These data confirms various indirect 
evidence of oxidative stress in CRPS-I patients and strengthen the justification for the use of 
antioxidants and free radical scavengers in the treatment and prevention of CRPS-I. This is 
proven by the positive outcomes of randomised clinical trials in human CRPS, wherein 
scavengers, such as dimethylsulfoxide are effective in the early treatment (Albazaz et al., 
2008). 
 
 
1.1.7.4. Cortical re-organization 
 
 
 
Continuous nociceptive contribution by hypoxia, inflammation, or sympathetic stimulation 
may lead to sensitization and alterations in cortical organization of sensory and motor units. 
Some CRPS patients experience referred sensations or body perception disturbances that are 
in line with the studies that demonstrate altered brain activation patterns (Maihofner et al., 
2005) and sensory mapping (de Mos et al., 2009d). One major finding was that watching a 
mirror image of the stimulated unaffected limb evokes pain in the affected limb when the 
stimulated area corresponded to the area of allodynia (Swart et al., 2009). 
 
In CRPS patients, changes in motor cortex representation, mislocalisations of noxious 
stimuli, changes in size and organization of the somatosensory map, and body perception 
disturbances are some features of cortical reorganization (Raja, 2009; Swart et al., 2009). 
Some patients exhibit abnormal or shifted brain activity to motor tasks, imagined motor tasks 
and show that the extent of observed functional re-organizations is linked to the properties of 
CRPS pain (Gieteling et al., 2008). A direct correlation has been exhibited between the extent 
of cortical re-organization and the level of pain perceived in CRPS. The reduction of pain in 
CRPS patients was associated with the changes on the somatotopic map (McCabe and Blake, 
2008). 
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1.1.7.5. Immunological disturbances 
 
 
 
Proinflammatory cytokines are linked to chronic pain, inflammation and also CRPS (Milligan 
and Watkins, 2009). Both in CRPS patients and CRPS animal models the skin is the primary 
source of the pro-inflammatory cytokines. Extensive studies are being done to measure the 
levels of pro-inflammatory mediators in the skin blister fluids of patients with CRPS. It has 
been showed that samples from the affected limb had higher concentrations of TNF-D, IL-1E 
compared to the unaffected side (Groeneweg et al., 2008b; Groeneweg et al., 2006; 
Heijmans-Antonissen et al., 2006; Huygen et al., 2002). Although numerous studies suggest 
that the keratinocytes and mast cells are the primary candidates none of the studies proved the 
exact cellular source of these cytokines (Li et al., 2010; Li et al., 2012; Li et al., 2009b; Wei 
et al., 2012). A recent study showed that among 148 patients, 36% of patients had increased 
levels of numerous cytokines such as Interferon-J, IL-1E, IL-2, IL-6, IL-7, IL-8, IL-10 
(Alexander et al., 2012; Wesseldijk et al., 2008a, b). In some patients, the CSF (cerebrospinal 
fluid) had up-regulated proinflammatory cytokines and other mediators such as glutamate and 
Nitric Oxide (NO) (Alexander et al., 2005). 
 
 
1.1.7.6. Genetic predisposition 
 
 
 
Genetic determinants may play a role in the predisposition of CRPS such as familial case 
reports of CRPS/RSD/algodystrophy (de Rooij et al., 2009; Shirani et al., 2010). These 
patients often reported to have early onset of disease, spreading of disease to multiple sites or 
dystonia. In few cases, the affected siblings show identical HLA profiles. A Dutch study 
showed that HLA-DQ1 was significantly more frequently observed in 52 CRPS patients 
compared to 295 regional controls. Few studies showed that HLA-DR13, HLA DR-DQ 
genotypes were seen in majority of patients in a cohort study. But, a clear pattern explaining 
the inheritance is yet to be determined (Kemler et al., 1999; van de Beek et al., 2000; van 
Hilten et al., 2000). 
 
Primarily warm CRPS has been associated with a polymorphism in one of the TNF-D 
promoter genes and homozygosity for this allele increased the involvement of more than one 
extremity. The ACE I/D polymorphism was increased in a small population of 14 Japanese 
CRPS patients (Kimura et al., 1998) but not in the European study of 60 patients (de Mos et 
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al., 2009d; Huhne et al., 2004). These studies shows that the deletion/deletion of ACE gene 
was overrepresented in CRPS I patients. Genetic disorders of mitochondrial DNA may also 
be associated with clinical manifestation of CRPS according to the study done in a Genetics 
clinic with approximately 500 children (Higashimoto et al., 2008). Polymorphism distribution 
of various cytokine, neurotransmitter and adrenoreceptor genes were also observed in a study 
that was held in northern German patients who did and did not develop CRPS I after distal 
radial fracture surgery. These patients reported a significant association of polymorphism in 
the D1a - adrenoreceptor gene (Herlyn et al., 2010). Although, exact relations between HLA 
features and CRPS are not yet clear but the current data suggest a possible genetic 
predisposition of CRPS. 
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1.2.1. Autoimmunity 
 
 
 
Autoimmunity is a condition in which the organism fails to recognize between the ‘self’ and 
‘non-self’ antigens and elicits an immune response against its own body tissues. Antibodies 
are immunoglobulins produced by the immune system against foreign bodies such as 
bacteria, virus, parasites etc., whereas autoantibodies represent immune responses against the 
body’s self-components. 
 
 
 
1.2.2. Autoantibodies against cell surface receptors 
 
 
 
Autoantibodies can bind to cell surface receptors and can cause diseases either by stimulating 
a receptor or blocking its stimulation by its natural ligand. Few examples are: Myasthenia 
gravis in which autoantibodies alter the acetylcholine receptor reorganization on the post-
synaptic muscle membrane and block acetylcholine neurotransmission functionally and these 
autoantibodies are responsible for fatal weakness (Vincent, 2002). Some subsets of epilepsy 
patients harbor serum autoantibodies to either glutamate/AMPA receptor or double-stranded 
DNA (dsDNA), which enter the blood-brain barrier and might kill neurons in brain fluids 
after hemispherotomy (Ganor et al., 2004; Ganor et al., 2005; Levite, 2002). In Graves’ 
disease, the autoantibodies are produced against Thyroid-Stimulating-Hormone receptor 
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(TSH) in the thyroid cells and stimulate excessive production of thyroid hormone. Recently, 
it has been shown autoantibodies to B-cells stimulate cellular activation of EBV (Epstein-
Barr virus), which is a human herpes virus that is the causative agent of infectious 
mononucleosis. Moreover, autoantibodies (autoAbs) against anti-M3 muscarinic 
acetylcholine receptor (M3R) were identified in sera of around 50% of patients with 
 
Sjögren’s syndromes (SS), and several B cell epitopes have been identified including the 1st, 
2nd and 3rd loop of Muscarinic 3 receptor (Sumida et al., 2012). 
 
 
1.2.3. Autoantibodies against nervous system 
 
 
 
Paraneoplastic neurological syndromes (PNS) are nervous system dysfunctions in cancer 
patients and have antineuronal antibodies and anti-synaptophysin autoantibodies (Blaes and 
Tschernatsch, 2008; Tschernatsch et al., 2008). These autoantibodies are the result of a cross-
reactive immune process directed against tumor and nervous system antigens. Autoantibodies 
against surface-binding receptor or ion channels are thought to be pathogenic in the 
paraneoplastic syndrome (Blaes, 2012). PNS has highly specific autoantibodies against 
onconeuronal antigens. It has been reported that these pathogenic receptor autoantibodies can 
cause limbic encephalitis (Blaes and Tschernatsch, 2010). Autoantibodies against CNS 
structures were observed in children with OMS (Opsoclonus-myoclonus syndrome) and their 
parents exhibiting some unspecific autoantibodies could a possible explanation for the 
genetic susceptibility of OMS in pediatric patients (Blaes et al., 2007a). Besides 
autoantibodies against intracellular proteins (anti-Hu, alpha-enolase, and KHSRP), specific 
binding of autoantibodies to the surface of neuroblastoma cells and cerebellar granular 
neurons have been found (Blaes et al., 2005; Blaes et al., 1998; Kirsten et al., 2007; 
Tschernatsch et al., 2007). Autoantibodies against Myelin Oligodendrocyte Glycoprotein 
(MOG) were described in patients with inflammatory demyelinating diseases of the CNS, 
including multiple sclerosis (Tsuburaya et al., 2014). KIR4.1 specific autoantibodies are 
potassium channel antibodies and seen in children with acquired demyelinating disease 
(Kraus et al., 2014). 
 
Autoimmune encephalitis is a new category of treatment-responsive encephalitis associated 
with antibodies to neuronal cell membrane antigens, including voltage-gated potassium 
channel (VGKC), N-methyl-D-aspartic acid receptor (NMDAR), alpha-amino-3-hydroxy-5- 
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methyl-4-isoxazolepropionic acid receptor (AMPAR), gamma-aminobutyric acid (GABA) B 
receptor and other antigens that have not yet been characterized. Among the different forms 
of this encephalitis, anti-NMDAR antibodies have been studied extensively in the recent 
years and some studies show that the autoantibody bind to extracellular conformational 
epitope in the NR1/NR 2 heteromers of the NMDAR. This disorder often affects young 
women with ovarian teratoma as a paraneoplastic syndrome (PNS) but may also affect 
women and men without an underlying tumor (Iizuka, 2008; Iizuka and Hara, 2009; Iizuka 
and Sakai, 2008; Iizuka et al., 2010). Autoantibodies targeted against voltage-gated 
potassium channel (VGKC)-associated proteins have been identified in limbic encephalitis 
(LE) and acquired neuromyotonia (aNMT) (Park et al., 2014). 
 
 
1.2.4. G-Protein Coupled Receptors (GPCRs) 
 
 
 
GPCRs, heptahelical, seven transmembrane (7TM) receptors, are a family of integral 
membrane proteins which possess seven membrane-spanning domains and are linked to a 
guanine nucleotide-binding protein (heterotrimeric G protein) (Peeters et al., 2011). 
Adrenergic, chemokine, olfactory, muscarinic cholinergic, opioid, neurotransmitter and 
rhodopsin receptors also belong to the family of GPCRs. These GPCRs are activated by an 
external signal such as ligands or other signal mediators. After binding of a ligand to its 
respective receptor, a conformational change takes place in the receptor leading to the 
activation of a G-Protein. GPCRs include receptors for sensory signal mediators such as 
adenosine, bradykinin, endothelin, neuropeptide Y, GABA (J-aminobutyric acid), opioid 
peptides, growth factors, vasopressin, tachykinins, chemokines, lipid mediators of 
inflammation includes prostaglandins and platelet-activating-factor, peptide hormones (eg., 
calcitonin, acetylcholine for muscarinic effect, serotonin) and biogenic amines (dopamine, 
epinephrine, norepinephrine, histamine, glutamate, neurokinin, oxytocin) . Activation of 
GPCRs with their ligand causes desensitization (either homologous desensitization in which 
the activated GPCR is down-regulated or heterologous in which the activated GPCS down-
regulates another GPCR). GPCR downregulation mostly ends up in the phosphorylation of 
the intracellular or cytoplasmic receptor by protein kinases. Phosphorylation by cAMP-
dependent protein kinases (Protein kinase A or PKA) is activated via adenylate cyclase and 
cyclic AMP (cAMP). In 2-adrenoreceptors, this kind of phosphorylation results in switching 
of coupling from the G0 to Gi class of G-protein. An example of this type is the dopamine 
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receptor D2 activation via 2-adrenoreceptors. GRKs or G-protein coupled receptor kinases 
are protein kinases phosphorylate only active GPCRs. The phosphorylation of this kind may 
result either in translocation or E-arrestin linking. Physiological roles of GPCRs include 
regulation of immune system activity and inflammation, cell density sensing, autonomic 
nervous system transmission, behavioral and mood regulation Fig. 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.5. Functional autoantibodies against ADRB2 & CHRM2 in CRPS 
 
 
 
The neuroautoimmune responses are determined by how infiltrating leukocytes react to 
autoantibodies, which bind to autoantigens located on the surfaces of neuronal and glial cell 
targets. In this case, the initiation of CRPS is due to the development of autoantibodies 
develop against the 2AR and M2R neurotransmitter receptors by breakdown of 
immunologic self-tolerance (Cooper and Clark, 2013). Autoimmune etiology in CRPS 
patients is a new pathophysiological concept in chronic pain. (Blaes et al., 2007b). Blaes et 
al. showed through competitive binding assay that sera from patients with CRPS showed 
autoantibodies against structures of autonomic nervous system (Blaes et al., 2004). Our group 
and others also demonstrated an increased prevalence of antibodies to parvovirus B19 in 
CRPS patients (Goebel, 2001; van de Vusse et al., 2001). Additionally, patients with 
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autoimmune autonomic neuropathy also reported autoantibodies to ganglionic acetylcholine 
 
receptors (Vernino et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Possible mechanism of action and potential autoantibody binding sites in CRPS patients for Beta-2-adrenergic ( 2AR) and 
 
Muscarinic-2 acetylcholine receptor M2R autoantibodies. (A) Autoantibody-binding site are available for 2AR are located in the CNS, 
heart, cerebellum, sympathetic autonomic nervous system, astrocytes and microglia. (B) Generation of pain in skeletal muscles and 
possible mechanism of action and potential autoantibody binding sites in CRPS patients for Muscarinic-2 acetylcholine receptor (M2R) 
autoantibodies. Autoantibody-binding site are available for M2R in the parasympathetic autonomic nervous system, heart, pyramidal 
motor pathway to skeletal muscles, motor cortex, peripheral nerves and thalamus (Cooper and Clark, 2013). 
 
 
 
 
Surface-binding autoantibodies against an inducible autonomic nervous system autoantigen 
are found in 30–40% of CRPS patients (Kohr et al., 2009). In another study by Kohr et al., 
functionally active autoantibodies against 2 adrenergic receptor and M2 muscarinic receptor 
were present in CRPS patients’ serum (Kohr et al., 2011). A recent study determined that 
passive transfer of serum IgG from CRPS patients resulted in behavioral and motor 
impairment in mice (Goebel and Blaes, 2013; Goebel et al., 2011). In CRPS IgG-transfer-
trauma model, mice developed clinical and laboratory features similar to that of the human 
disease condition (Tekus et al., 2014). Potential autoantibody binding sites for 2AR and 
M2R in CRPS patients is shown in Fig. 3 (Cooper and Clark, 2013). 
 
 
1.2.6. Vascular and bone-related disturbances in CRPS 
 
 
 
CRPS patients repeatedly report vascular disturbances as mentioned above. Molecular level 
understanding of the clinical progression that leads to severe vascular disturbances is still 
lacking. As mentioned above, most of the CRPS patients have peripheral nerve injury and a 
pattern of vascular leakage could be expected in these patients. Vascular disturbances are 
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commonly found in CRPS patients. Vascular leakage is a crucial step by which the 
autoantibodies gain access to the neuroautoantigens of CRPS patients. Our group found 
autoantibodies against neuronal epitopes in CRPS patients (Kohr et al., 2009). Regulation of 
these surface receptors may be controlled by the accumulation or activation by the 
autoantibodies and likely to initiate inflammatory responses (Cooper and Clark, 2013). There 
are many hypotheses, which states that vascular lesions can be a main reason behind many 
neuroinflammatory diseases (Mayer et al., 2010). The questions that remains unanswered was 
do CRPS patients have autoantibodies against vascular structures (endothelial cells) and how 
far they contribute to the pathophysiology of this painful disease. 
 
Bone related issues are obvious in CRPS patients. The mechanism that causes osteoporosis in 
CRPS patients is poorly understood. Numerous studies have shown that -Adrenergic 
receptors (AR) play an important role in regulating bone remodeling. The expression of -
Adrenergic receptor kinase-like activity and -arrestin was observed in osteoblasts (Bliziotes 
et al., 1996). Among the AR, hypothalamic 1 and 2-adrenergic system stimulates bone 
formation while the 2AR in bone tissue activate osteoclastogenesis and increase bone 
resorption (Zofkova and Matucha, 2014). Various studies supports impaired wound healing 
and exacerbating inflammation via a novel crosstalk between adrenergic and toll-like receptor 
pathways in BM-MSCs (Bone-marrow derived mesenchymal stem cells) and (neonatal 
keratinocytes) NHKs (Dasu et al., 2014). Gianfagna et al. did a study in European children 
and showed that the Neuromodin U (NMU) plays an important role in regulating the bone 
strength and this regulation is mediated through ADRB2 gene (Gianfagna et al., 2013). 
Additionally, studies show that in BMMs (bone marrow macrophages) and RAW 264.7 cells 
Reactive Oxygen species (ROS) acts as a regulatory molecule and induces osteoclastogenesis 
via E-Adrenergic receptor signaling (Kondo et al., 2013). Numerous studies have shown that 
patients with hip fractures were treated successfully with beta-blockers (such as propranolol 
hydrochloride) (Zofkova and Matucha, 2014). Some studies show that CRPS patients have 
elevated levels of osteocyte activity (Boyce et al., 2006; Bucay et al., 1998). While some 
studies revealed that OPN (osteopontin) plays a major role in sympathetic tone regulation of 
bone mass takes place through the modulation of 2AR/cAMP signaling system (Nagao et 
al., 2011). Model of regulation of 2AR signaling by OPN is shown in Fig. 4. Other 
controversial discussions are available which says OPG (Osteoprotegerin) might play a 
protective role and can be used as a biomarker for impaired bone metabolism in CRPS 
(Boyce and Xing, 2007; Kramer et al., 2014). 
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1.3.1. Pharmacological therapeutic approaches 
 
 
 
Pharmacological treatments are mainly to provide pain relief and to accelerate physical 
rehabilitation. Unfortunately, in RCTs, oral, topical, and intravenous medications targeting 
the sympathetic nervous system and D-adrenergic receptors (clonidine) have not been proven 
effective. 
 
Opiods, anticonvulsants and antidepressants are most commonly used in other neuropathic 
pain conditions but have not been extensively studied in CRPS. Immunomodulating agents 
such as infliximab and thalidomide were successful in few CRPS studies (Bernateck et al., 
2007). Intriguingly, potent anti-inflammatory agents such as corticosteroids have shown to be 
beneficial for CRPS in RCTs (de Mos et al., 2009d; Kalita et al., 2006; van Rijn et al., 2009). 
Use of Gabapentin in patients with CRPS showed positive results (Mellick, 1995; Mellick 
and Mellick, 1995; van de Vusse et al., 2004). 
 
Glucocorticoids use in CRPS patients have shown positive effect as they help in inhibiting 
the expression of neuropeptides, pro-inflammatory cytokines such as TNF-D, IL-1 etc., and 
inflammatory mediators like prostaglandins (Bernateck et al., 2007; Guo et al., 2006; Huygen 
et al., 2004; Kingery et al., 2001a; Kingery et al., 2001b; Piedimonte et al., 1991). To reduce 
limb sensitivity and swelling, low-dose local anaesthetics (ropivacaine and levo-bupivacaine) 
are used with corticosteroids (methyl prednisolone, triamcinalone, and beclomethasone) or 
clonidine in nerves blocks (peripheral, plexus, or neuraxis). Apart from this, supporting 
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studies showed that free radical scavengers like fatty cream with 50% DMSO in RCTs 
showed improvement in inflammatory signs and pain (Zuurmond et al., 1996). At present, it 
is not possible to determine the effect of sympathetic blockade (with local anaesthetic) on 
long-term pain relief (Cepeda et al., 2005). The effect of sympathetic blockade is unclear, 
with some studies showing brief benefit and others showing no beneficial effects and most 
important is to consider about the small group of patients (Albazaz et al., 2008; de Mos et al., 
2009d). 
 
Intravenous Immunoglobulin (IvIg) is used to treat immunodeficiency and autoimmune 
disorders. Recently, IvIg has been successfully used to treat chronic CRPS (Goebel et al., 
2010; Goebel et al., 2005). In another study a young patient who developed CRPS secondary 
to sciatic compression was treated with high dose of IvIg (2g/kg) and recovered completely 
within 10 days after infusions (Medlin et al., 2013). An open study was made to determine 
the immunoglobulin maintenance in treating long-standing CRPS (Goebel et al., 2013). 
Ketamine, magnesium or tadalafil have been shown to be effective in treating CRPS 
(Birklein and Sommer, 2010; Collins et al., 2009; Groeneweg et al., 2008a; Schwartzman et 
al., 2009a). Other therapeutic approaches such as using inhibitors of osteoclasts activity were 
also shown to be convincing for the treatment of CRPS mediated bone disturbances. 
Bisphosphonates (clodronate, alendronate, and ibandronate) have been studied in controlled 
trials and showed the potentiality to reduce pain associated with bone loss in patients with 
CRPS I (Albazaz et al., 2008; Brunner et al., 2009). Use of calcitonin showed positive effects 
on pain but it failed to show positive effects on CRPS-mediated osteoporosis (Forouzanfar et 
al., 2002; Gobelet et al., 1992; Perez et al., 2001). 
 
 
1.3.2. Non-pharmacological therapeutic approaches 
 
 
 
Non-pharmocological therapies are often physiotherapy, exercise and other activities in 
which the patients are actively involved and aimed at improving or restoring the affected 
limb. A recent systematic review showed that spinal cord stimulation was effective in 
reducing the chronic neuropathic pain of CRPS type I (Simpson et al., 2009). Transcutaneous 
electric nerve stimulation (TENS) is another kind of anelgetic therapy which showed 
reduction of pain in patients with CRPS (Robaina et al., 1989). 
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A potential beneficial effect was demonstrated in studies with physiotherapy and cognitive 
behavioral therapy. No relation between psychological factors and CRPS were shown in 
majority of studies (de Mos et al., 2009d). Due to lack of high-quality methodological studies 
the actual association between psychological factors and CRPS remains controversial. The 
severe chronic pain and disability of CRPS may cause psychological distress. Experts 
emphasize the need for psychological and behavioral therapy as part of optimal treatment 
programs for CRPS patients (Bruehl and Chung, 2006; de Mos et al., 2009d). Co-morbidities, 
such as depression and anxiety, should be treated concurrently. Extreme fear for pain can 
lead to disuse of the affected extremity, thereby making a feasible contributor to the disease 
course of CRPS (de Mos et al., 2009d). 
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Complex regional pain syndrome (CRPS) is a painful condition in which patients are 
profoundly affected with decreased ability to participate in normal activities of daily living. 
An increased interest in CRPS has driven the understanding of the pathophysiology of this 
painful disease. Studies have shown a possible involvement of immune system and 
development of autoimmune harmony in CRPS. Our group has shown that these patients 
exhibit autoantibodies against 2-adrenergic and M2 muscarinic receptors. However, the role 
of functionally active autoantibodies is yet to be illustrated. Therefore, the main objectives of 
this study were: 
 
 
 
1. To investigate the contribution of autoantibodies in development of the local trophic 
changes in the affected limb. 
 
2. To identify the mechanism of functional autoantibodies in mediating the 
inflammation in vascular and bone cells. 
 
3. To determine the possible therapeutic role of Intravenous Immunoglobulin (IvIg) as a 
new treatment option for CRPS. 
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Serum was obtained from 13 clinically defined CRPS patients according to the IASP 
diagnostic criteria (Bruehl et al., 1999; Harden et al., 2007) after informed consent and 
approval from the ethical committee of the Johannes-Gutenberg-University Mainz. Sera of 11 
sex and age matched healthy controls (HC) and 7 radial fracture (RF) patients (who did not 
develop CRPS) served as controls. None of the healthy controls or radial fracture patients had 
a history of chronic neuropathic pain. Table 3 shows the detailed clinical and immunological 
data of the CRPS patients. 
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3.2.1. Chemicals, acids and bases 
 
 
 
Compounds Company 
Acetic acid Merck KGaA, Darmstadt, Germany 
  
Ammonium Persulphate (APS) Carl Roth, Karlsruhe, Germany 
  
Agarose Bioline GmbH, Luckenwalde, Germany 
  
Atropine Sigma-AldrichChemieGmbH,Taufkirchen, 
 Germany 
  
Bovine Serum Albumin (BSA) Sigma-AldrichChemieGmbH,Taufkirchen, 
 Germany 
  
Bromophenol Blue Neolab, Heidelberg, Germany 
  
Disodium hydrogen phosphate (Na2HPO4) Merck KGaA, Darmstadt, Germany 
Distilled water (Ecostrain®) Braun, Melsungen, Germany 
  
Dimethylsulfoxide (DMSO) Carl Roth, Karlsruhe, Germany 
  
DNase Qiagen, Hilden, Germany 
  
EDTA Carl Roth, Karlsruhe, Germany 
  
Ethanol 100% Sigma-AldrichChemieGmbH,Taufkirchen, 
 Germany 
  
FBS PAA Laboratories, Pasching, Austria 
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  Glycerol   Carl Roth, Karlsruhe, Germany 
      
 Glycin   Merck KGaA, Darmstadt, Germany  
      
 Isopropanol   Merck KGaA, Darmstadt, Germany  
      
 Methanol   Merck KGaA, Darmstadt, Germany  
     
 2-Mercaptoethanol  Sigma-AldrichChemieGmbH,Taufkirchen,  
    Germany  
      
 NP40   US Biologicals, Swampscott, MA  
     
 Paraformaldehyde (PFA)  Sigma-AldrichChemieGmbH,Taufkirchen,  
    Germany  
     
 Potassium chloride (KCL)  Merck KGaA, Darmstadt, Germany  
      
 Potassium dihydrogen phosphate Merck KGaA, Darmstadt, Germany  
 
(KH2PO4)     
     
 10x PBS for cell culture (DPBS)  Lonza, Köln, Germany  
      
 2-Propanol   Sigma-AldrichChemieGmbH,Taufkirchen,  
    Germany  
     
 RNAse free water  Millipore corporation, MA, USA  
    
 Rotiphorese Gel (30% acrylamide mix) Carl Roth, Karlsruhe, Germany  
     
 Sodium chloride (NaCl)  Carl Roth, Karlsruhe, Germany  
    
 
Sodium hydrogen carbonate (NaHCO3) Merck KGaA, Darmstadt, Germany  
 
Sodium dihydrogen phosphate (NaH2PO4) Merck KGaA, Darmstadt, Germany  
 
Sodium azide (NaN3)  Merck KGaA, Darmstadt, Germany  
 Sodium Dodecyl Sulfate (SDS)  Neolab, Heidelberg, Germany  
    
 Trishydroxymethyl aminomethane (Tris) Carl Roth, Karlsruhe, Germany  
      
 Tryphan blue   Carl Roth, Karlsruhe, Germany  
    
 Tris acetate-EDTA buffer (TAE) 10x Carl Roth, Karlsruhe, Germany  
      
 Tris HCl   Carl Roth, Karlsruhe, Germany  
     
 Trypsin (2.5 g/l)  Gibco, Invitrogen, Carlsbad, USA  
      
 Tween 20   Merck KGaA, Darmstadt, Germany  
      
 TEMED   Carl Roth, Karlsruhe, Germany  
    
 Intravenous Immunoglobulin (IvIg) TalecrisbiotherapeuticsGmbH,Frankfurt,  
 
Gamunex® 10% 
 Germany  
    
 Bovine serum Albumin fraction V Merck KGaA, Darmstadt, Germany  
     
 Non-fat dry milk powder  Cell Signaling Technology, MA, USA  
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  Cell lysis buffer (10x)   Cell Signaling Technology, MA, USA 
     
3.2.2. Laboratory consumables    
      
   Consumables   Company 
 Cellstar® 6 Well and 24 well Cell Culture GreinerBioOne, Frickenhausen, Germany  
 Plate      
    
 Cellstar® Plastikpipettes (5 ml, 10 ml) GreinerBioOne, Frickenhausen, Germany  
    
 Cellstar®U-shapewithLid,TC-Plate,96 GreinerBioOne, Frickenhausen, Germany  
 well, sterile      
    
 Cellstar® Flat bottom withLid, TC-Plate, GreinerBioOne, Frickenhausen, Germany  
 96 well, sterile     
     
 
Cellstar® 75 cm2 Cell cultur flasks 
 GreinerBioOne, Frickenhausen, Germany  
     
 
Cellstar® 125 cm2 Cell cultur flasks 
 GreinerBioOne, Frickenhausen, Germany  
      
 Cell scrapper   GreinerBioOne, Frickenhausen, Germany  
      
 Cryobox 136x136x130 mm   Ratiolab GmbH, Dreieich, Germany  
    
 Cryo TubeTM vials (1,8 mL; 4,5 mL) Sarstedt AG & Co, Nümbrecht, Germany  
       
 Polysterene disposable cuvettes for Ratiolab GmbH, Dreieich, Germany  
 Bradford assay     
    
 FACS-Tubes 0,5 mL 38 x 6,5 mm PS Sarstedt AG & Co, Nümbrecht, Germany  
    
 Falcon5mLPolystyreneRound-Bottom Becton Dickinson, Heidelberg, Germany  
 Tube      
      
 Falcon tubes (15 ml, 50 ml)   Becton Dickinson, Heidelberg, Germany  
     
 Glass Pasteur pipettes 150 mm  Brand, Wertheim, Germany  
    
 Ministart single use  filter (0,2  m, 0,45 SartoriusStedimBiotechGmbH,Göttingen,  
 m)    Germany  
     
 Nitra-Tex® powder free gloves  B. Braun Melsungen AG, Germany  
       
 Parafilm    Pechiney Plastic packaging, Menasha, WI  
    
 Pipette tips withoutfilter (10 L, 100 L, Sarstedt AG & Co, Nümbrecht, Germany  
 1000 L)      
     
 Eppendorf tubes 1,5 mL, 2 mL  EppendorfVertriebDeutschlandGmbH,  
     Wesseling-Berzdorf, Germany  
       
 Eppendorf tubes1,5mL, 2mL (PCR Nerbe Plus GmbH, Winsen (Luhe), Germany  
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clean- pyrogen & DNase free)      
     
Servapor® dialysis tubing (6 mm, 25 mm) Serva Electrophoresis GmbH, Heidelberg, 
   Germany   
  
S-Monovette® 7,5 mL Z (Serum-Tubes) Sarstedt AG & Co, Nümbrecht, Germany 
  
Sterile PCR- clean pyrogen & DNase free Nerbe Plus GmbH, Winsen (Luhe), Germany 
with filter (10, 100, 200, 1000 µl)      
  
Tissue culture dishes steril 35,0 / 10 mm GreinerBioOne, Frickenhausen, Germany 
     
UV-Spectroscopic cuvettes (RNA BioRad, München, Germany  
quantification)       
  
Falcon® Plastic pipettes 25 ml, 10 ml, 5 ml Becton Dickinson, Heidelberg, Germany 
   
Glasswares (different sorts)  Fisherbrand; IDL; Schott&Gen; Simax 
    
Syringe 25 ml for BSA   B. Braun Melsungen AG, Germany 
  
Syringe5ml,10mlforserumfiltration B. Braun Melsungen AG, Germany 
   
Nitrocellulose membrane  GEHealthcare,AmershamTMHybondECL, 
   Buckinghamshire, UK   
    
PCR Tube-strips   Applied Biosystems, Darmstadt, Germany 
    
PCR Cap-strips   Applied Biosystems, Darmstadt, Germany 
    
Dialysis clips   Ratiolab GmbH, Dreieich, Germany 
  
Safety-Multifly®–Set, sterile, pyrogenfree Sarstedt AG & Co, Nümbrecht, Germany 
(Cannulae)       
   
Grid inserts for Cryobox  Ratiolab GmbH, Dreieich, Germany 
      
3.2.3. Laboratory instruments      
     
Instruments   Company  
ELISA-Reader Multiscan EX 
 Thermoelectroncorporation,Langenselbold, 
 
Germany 
  
     
       
Fusion FX7 chemiluminescence system 
Peqlab Biotechnologie GmbH, Erlangen, 
Germany 
  
     
   
Neubauer improved Haemocytometer Brand, Wertheim, Germany  
   
SmartSpecTM Plus Spectrophotometer BioRad, München, Germany  
   
Trans-Blot® SD Semi-dry transfer cell BioRad, München, Germany  
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 Nanophotometer Implen GmbH, München, Germany   
    
 StepOne® Real-Time PCR system Applied Biosystems, Darmstadt, Germany  
    
 
Light Microscope for cell culture 
Carl Zeiss Microscopy GmbH, Oberkochen  
 
Germany 
   
     
    
 BD FACS Calibur BD Biosciences, Heidelberg, Germany  
    
 Hettich centrifuge (cooling) Hettich GmbH, Kirchlengen, Germany  
    
 Magnetic stirrer IKA£ Werke GmbH, Staufen, Germany  
    
 Centrifugetype2-6Easiashaker Sigma-AldrichChemieGmbH,Taufkirchen,  
 Medgenix diagnostics Germany    
    
 Centrifuge Universal 32 R (cell culture) Hettich GmbH, Kirchlengen, Germany  
      
 NuaireTM Biological Safety Cabinets Class INTEGRABiosciences GmbH, Fernwald, 
 II type A/B3 (Sterilbank) Germany    
    
 
Arpege 75, Liquid nitrogen tank 
AirLiquideMedicalGmbH,Düsseldorf,  
 
Germany 
   
     
      
 NalgeneTM Cryo 1°C Freezing container Nalgene®, Germany    
    
 pH-Meter Mettler Toledo GmbH, Giessen, Germany  
      
 
Pipette boy 
INTEGRABiosciences GmbH, Fernwald, 
 
Germany 
   
     
       
 
Power pack 
Peqlab Biotechnologie GmbH, Erlangen, 
 
Germany 
   
     
       
 
ProSpec (Nephelometer) Dade BehringMarburg GmbH, Marburg, 
 
Germany 
   
     
    
 
Pump P-1 (Pump for IgG purification) GE Healthcare Europe GmbH, Freiburg,  
 
Germany 
   
     
      
 Refrigerators and freezers Different companies    
    
 
Rotamax 120 (Shaker) Heidolph Instruments GmbH & Co. KG,  
 
Schwabach, Germany 
   
     
       
 
Swivel platform 
Peqlab Biotechnologie GmbH, Erlangen, 
 
Germany 
   
     
     
 
Sanyo Incu-safe incubator for cell culture 
Ewald InnovationstechnikGmbH,Bad 
 
Nenndorf, Germany 
   
     
    
 Table top centrifuge EBA 20 Hettich GmbH, Kirchlengen, Germany  
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  Table top centrifuge micro 120 Hettich GmbH, Kirchlengen, Germany 
     
 
Vortexer vortex-Genie2 
Heidolph Instruments GmbH & Co. KG,  
 
Schwabach, Germany 
 
    
     
 
Weighing balance 
SartoriusStedimBiotechGmbH,Göttingen,  
 
Germany 
 
    
    
 Water bath Memmert GmbH + Co.KG, Germany  
    
 HiTrap¥proteinGHP(1mLund5mL GEHealthcareEuropeGmbH,Freiburg,  
 Protein G columns) Germany  
     
 
Fluorescence microscope 
Carl Zeiss Microscopy GmbH, Oberkochen  
 
Germany 
 
    
    
 Gel tank for western blotting BioRad, München, Germany  
    
 Combs for western blotting BioRad, München, Germany  
    
 Gel casting trays and frames BioRad, München, Germany  
     
 
BEP 2000 Advance (ELISA-Reader) DadeBehringMarburgGmbH,Marburg,  
 
Germany 
 
    
    
 
 
3.2.4. DNA and Protein ladders 
  
 
 
  
 
 
Markers Company 
PageRulerTM Plus Prestained Protein 
Ladder 
Fermentas, Invitrogen, Carlsbad, USA 
Spectra Multicolor Broad Range 
Protein Ladder 
Thermo Fischer Scientific, Rockford, USA 
Fluorescent Long Range DNA Ladder Jena Bioscience, Jena, Germany 
 
 
3.2.5. Buffers 
 
Buffers Components Volume 
1X SDS-PAGE Running Buffer Carl Roth, Karlsruhe, Germany 
(Rotiphorese® 10X SDS-PAGE) 
H2O 
100ml 
 
900ml 
10x PBS (1 Liter) 137mM NaCl   
 
80g 
  



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2 mM KH2PO4 2.4 g 
  2.7 mM KCl 2 g  
  
10 mM Na2HPO4 14.4 g  
  
H2O 1000 ml  
  pH 7.4  
     
 10x TBS (1 Liter) Tris 24.2 g  
  NaCl 87.7 g  
  
H2O 1000 ml  
  pH 7.2 to 7.6  
     
 1x TBS-Tween (TBST) (1 Liter) 1x TBS 100 ml  
 (Stored at RT) 0.1% Tween®20 1 ml  
     
 Lysis Buffer (250 ml) NaCl 2.19 g  
  Tris 0.61 g  
  EDTA 0.07 g  
  Glycerol 25 ml  
  NP40 2.5 ml  
  
NaN3 0.025 g  
  pH 7.4  
     
 6xSDS-PAGELoadingBuffer 60 mM Tris-HCl 36 ml (pH 6.8)  
 (Laemmli buffer) 2% SDS 60 ml  
  0.01% Bromophenol blue 60 mg  
  10% Glycerol 60 ml  
  
ddH2O 144 ml  
  ß-Mercaptoethanol 65 µl/ml  
     
 SDS-PAGETransferbuffer(1 10x Running buffer 100 ml  
 Liter) Methanol 200 ml  
  
ddH2O 700 ml  
     
 5%Non-fatdrymilk(blocking Milk powder 5 g  
 buffer) TBST 100 ml  
     
 Blocking buffer (5% BSA) Bovine Serum Albumin fraction V 5 g  
  TBST 100 ml  
     
 4% Paraformaldehyde (250 ml) Paraformaldehyde 4 g  
     
 0.1 M Glycine Buffer (500 ml) – Glycine 3.75 g  
     
   9
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  Washing buffer  H2O  500 ml 
    pH  9.0  
      
 0.1 M Glycine Buffer (100 ml) – Glycine  0.75 g  
 Elution buffer  H2O  100 ml  
    pH  2.7  
       
 1 M Tris HCl  pH  8.5  
       
 FACS Buffer (500 ml)  10x PBS  50 ml  
    10% FBS  5 ml  
    
10% NaN3  5 ml  
    
H2O  500 ml  
       
 10x Trypsin EDTA  10x Trypsin  5 ml  
    
ddH2O  45 ml  
       
 10%Ammonium Persulfate APS  1 g  
 (APS)   ddH2O  10 ml  
       
 10% Sodiumdodecylsulfate SDS  1 g  
 (SDS)   ddH2O  10 ml  
      
 1xCelllysisBuffer(Forprotein 20 mM Tris HCl    
 extraction of primary 150 mM NaCl    
 osteoblasts)  1 mM Na2EDTA    
    1 mM EDTA    
    1% Triton    
    2.5 mM sodium pyrophosphate   
    1 mM ß-glycerophosphate    
    1 mM Na3VO4    
    1 µg/ml leupeptin    
        
 
 
3.2.6. Molecular biology KITS and Assay reagents 
 
 
 
Kits Manufacturer Artikle Nr. Method 
peqGOLDTotal PeqlabBiotechnologieGmbH, 
12-6834-02 RNA Isolation 
RNA Isolation Kit Erlangen, Germany 
  
    
BCA Protein Assay Pierce®ThermoScientific,IL, 23225 Protein 
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  Kit     USA        quantification 
                
 QuantiTect®  Qiagen GmbH, Hilden,    Reverse  
 
Reverse 
    
205314 
 
    
Germany 
     
Transcription 
 
 
Transcription Kit 
         
              
                  
 Quanti   FastTM Qiagen GmbH, Hilden,    PolymeraseChain  
 
SYBRGreenPCR 
  
204156 
 
  
Germany 
     
Reaction (PCR)  
 
kit 
            
                 
                 
 iTaq Universal           
PolymeraseChain 
 
 
SYBR£ 
 
Green 
 
Bio-Rad, CA, USA 
   
172-5124 
 
      
Reaction (PCR)  
 
qPCR Master Mix 
           
              
                 
 Cell Proliferation Roche Diagnostics GmbH,  11644807 
Proliferation Assay 
 
 
reagent WST-1 
 
Mannheim, Germany 
   
001 
 
        
                
 Cytotoxicity  
Roche Diagnostics GmbH, 
 
11644793 
   
 
detection 
 
kit
  
Cytotoxicity assay 
 
   
Mannheim, Germany 
   
001 
 
 (LDH)           
                 
                
 Annexin-V-Fluos  
Roche Diagnostics GmbH, 
 
11988549 
   
 
Apoptosis Staining
  
Apoptosis staining 
 
  
Mannheim, Germany 
   
001 
 
 
kit 
          
                 
               
 Lipofectamine£  Lifetechnologies GmbH,  
13778-075 
siRNAmediated  
 
RNAiMAX reagent 
 
Darmstadt, Germany 
   
transfection 
 
        
               
 3.2.7. Primary antibodies           
                  
 Name  Host  Reactivity Mol.  Method Cat. No. Company   
   
Weight 
  
                 
 Anti-  
Rabbit 
 
H M 
 
46 kDa 
 FACS,  
ab61778 
Abcam plc,   
 
ADRB2 
    
WB 
 
Cambridge, UK 
  
            
               
 Anti-  
Mouse 
 
H M P R 64 kDa 
 FACS,  
ab2805 
Abcam plc,   
 
CHRM2 
   
WB 
 
Cambridge, UK 
  
            
                 
 
Anti- 
    
H M R 
      Cell Signaling   
  
Rabbit 
 
60 kDa 
 
WB 
 
9272 Technology, MA, 
  
 
Akt 
  
MK 
    
            
USA 
  
                
                 
               
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Anti-  
H M R 
   Cell Signaling  
pAkt Rabbit 60 kDa WB 4060s Technology, MA, 
 
MK 
 
(Ser473)     USA  
      
        
Anti- 
 
H M R 44/42 
  Cell Signaling  
Rabbit WB 9102 Technology, MA, 
 
Erk 1/2 MK kDa 
 
   
USA 
 
       
        
Anti- 
 H M R 
44/42 
  Cell Signaling  
Rabbit Mk Pg Sc WB 4370s Technology, MA, 
 
pErk 1/2 kDa 
 
 
Hm B Z 
  
USA 
 
      
        
Anti-Total 
 H M R    Cell Signaling  
Rabbit Mk GP 43 kDa WB 9212s Technology, MA, 
 
P38 MAPK 
 
 (C)    USA  
      
        
Anti-pP38      
Cell Signaling 
 
MAPK 
 
H M R 
    
Rabbit 43 kDa WB 9211s Technology, MA, 
 
(Thr180/ Mk  
    
USA 
 
Tyr182)       
       
        
Anti- 
 
H M R 84, 91 
  Cell Signaling  
Rabbit WB 9172 Technology, MA, 
 
Stat1 MK kDa 
 
   
USA 
 
       
        
Anti- 
  
84, 91 
  Cell Signaling  
Rabbit H M R WB 9171s Technology, MA, 
 
pStat1 kDa 
 
    
USA 
 
       
        
Anti- 
     Chemicon/  
Mouse Ca H M R 38 kDa WB MAB374 Millipore, 
 
GAPDH 
 
     
Temecula, CA 
 
       
        
Anti-  H M R 
46, 54 
  Cell Signaling  
Total Rabbit Hm Z B WB 9252 Technology, MA, 
 
kDa 
 
SAPK/JNK 
 
Sc 
  
USA 
 
     
        
      R&D Systems  
Anti-      GmbH,  
Collagen Sheep H 140 kDa WB Af6220 Wiesbaden-  
1D1      Nordenstadt,  
      Germany  
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3.2.8. Secondary antibodies 
 
 
 
  Antibody  Host Cat. No. Company   
  Anti-Rabbit HRP  Goat sc-2004 Santa Cruz Biotech, CA, USA 
         
  Anti-Mouse HRP  Donkey sc-2318 Santa Cruz Biotech, CA, USA 
         
  Anti-Goat HRP  Donkey sc-2020 Santa Cruz Biotech, CA, USA 
         
  Anti-Sheep HRP  Donkey sc-2473 Santa Cruz Biotech, CA, USA 
          
  
Anti-Human IgG/FITC Human F 0202 
DAKOCytomation, Glostrup, 
  
Denmark 
   
         
           
3.2.9. Softwares         
           
  Softwares   Company    
  Fusion X7 software   PEQLAB, Erlangen, Germany   
         
  Fusion BioID software  PEQLAB, Erlangen, Germany   
       
  GraphPad Prism version 4.00 GraphPadSoftware,SanDiego,California, 
     USA      
         
  Microsoftword, powerpoint,Excel Microsoft corporation    
 2010         
        
  Cell Quest software   BDCellQuestProsoftwareonMac®OSfor 
     flow cytometry    
       
  BEP 2000 SW V.1.23.4 (ELISA reader) Thermo Fischer Scientific, Rockford, USA 
        
  StepOne Software v2.1  AppliedBiosystemsbyLifetechnologies 
     GmbH, Darmstadt, Germany    
          
  Primer 3.0 online tool  http://primer3.ut.ee    
       
  Primer Blast NCBI online tool http://www.ncbi.nlm.nih.gov/tools/primer- 
     blast/      
           
3.2.10. Primer sequences        
        
   Primer name Primer sequence    Nucleotide ID 
  Hu BMP-2 Fw 5´- CCTCAGCAGAGCTTCAGGTT -3´  NM_001200.2  
        
  Hu BMP-2 Rv 5´- AATTCGGTGATGGAAACTGC -3´     
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  Hu TGFE-1 Fw 5´- GTACCTGAACCCGTGTTGCT -3´ NM_000660.5 
     
 Hu TGFE-1 Rv 5´- CACGTGCTGCTCCACTTTTA -3´   
     
 Hu MHC-I Fw 5´- CAGGACACTGAGCTTGTGGA -3´ NM_005514.6  
     
 Hu MHC-I Rv 5´- TCTTCTCCAGAAGGCACCAC -3´   
     
 Hu MHC-II Fw 5´- CTGGAACAGCCAGAAGGAAG -3´ NM_002124.3  
     
 Hu MHC-II Rv 5´- ACCTCGTAGTTGTGTCTGCAC -3´   
     
 Hu ICAM-1 Fw 5´- CAAGGCCTCAGTCAGTGTGA -3´ NM_000201.2  
     
 Hu ICAM-1 Rv 5´- GTGTCTCCTGGCTCTGGTTC -3´   
     
 Hu VCAM-1 Fw 5’- ACACTTGCTGCTGGTGATTC -3’ NM_001078.3  
     
 Hu VCAM-1 Rv 5’- ACACTTGCTGCTGGTGATTC -3’   
     
 Hu MCP-1 Fw 5’- ACACTTGCTGCTGGTGATTC -3’ NM_002982.3  
     
 Hu MCP-1 Rv 5’- ACACTTGCTGCTGGTGATTC -3’   
     
 Hu GAPDH Fw 5´- AATCCCATCACCATCTTCCA -3´ NM_001256799.  
   
1 
 
 Hu GAPDH Rv 5´- TGGACTCCACGACGTACTCA -3´  
     
 Ms GAPDH Fw 5´- ACTCCACTCACGGCAAATTC -3´ NM_008084.3  
     
 Ms GAPDH Rv 5´- CTCCTGGAAGATGGTGATGG -3´   
     
 Hu ADRB2 Fw 5´- CTGGTGCGAGTTTTGGACTT -3´ NM_000024.5  
     
 Hu ADRB2 Rv 5´- ATGGCAAAGTAGCGATCCAC -3´   
     
 Hu CHRM2 Fw 5´- GTCAAGCGGACCACAAAAAT -3´ NM_001006632.  
   
1 
 
 Hu CHRM2 Rv 5´- CCAGAAGAGAATGGCTGGAG -3´  
     
 CHO GAPDH Fw 5´- AAGAGGGTCATCATCTCCGC -3´ NM_001244854.  
   
2 
 
 CHO GAPDH Rv 5´- TGCTGACAATCTTGAGGGAGT -3´  
     
 Hu RANK Fw 5´- ATCTGGCCAAGAGGAGCAAG -3´ NM_033012.3  
     
 Hu RANK Rv 5´- TTGGAGATCTTGGCCCAACC -3´   
     
 Hu CTR Fw 5´- GCAATGCTTTCACTCCTGAGAAA -3´ NM_001164737.  
   
1 
 
 Hu CTR Rv 5´- ACACGAAAATCCCCAGGGAA -3´  
     
 Hu CTSK Fw 5´- TTCCGCAATCCCGATGGAATA -3´ NM_000396.3  
     
 Hu CTSK Rv 5´- GCAAAGCTCACCACAGGTAG -3´   
     
 Hu Col 1 Fw 5´- ACGTCCTGGTGAAGTTGGTC -3´ NM_000088.3  
     
 Hu Col 1 Rv 5´- ACCAGGGAAGCCTCTCTCTC -3´   
     
 Hu DKK 1 Fw 5´- AGCGTTGTTACTGTGGAGAAG -3´ NM_012242.2  
     
 Hu DKK 1 Rv 5´- GTGTGAAGCCTAGAAGAATTACTG -3´   
     
   "
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    Hu ALP Fw  5´- CCTCCTCGGAAGACACTCTG -3´  NM_000478.4 
           
  Hu ALP Rv  5´- AGACTGCGCCTGGTAGTTGT -3´      
           
  Hu TRAP Fw  5´- GATCCTGGGTGCAGACTTCA -3´  NM_001611.3   
           
  Hu TRAP Rv  5´- GCGCTTGGAGATCTTAGAGT -3´      
           
  Hu Integrin 3 5´- TCGAGTTCCCAGTGAGTGAG -3´  NM_000212.2   
  Fw             
           
  Hu Integrin 3 5´- GACAGGTCCATCAAGTAGTAG -3´      
  Rv             
            
  Hu Osteocalcin 5´- GGCGCTACCTGTATCAATGG -3´  NM_199173.4   
  Fw             
            
  Hu Osteocalcin 5´- TCAGCCAACTCGTCACAGTC -3´      
  Rv             
            
3.2.11. Cell culture medium and solutions       
          
   CHO-WT(wild     Basal medium 500 ml PAN 
  type)  DMEM/HAM’s F- 10% fetalbovine   Biotech  
    12 medium (with 1% serum (FBS) 50 ml GmbH,  
    L-glutamine   1% Penicillin/   Aidenbach,  
    15 mM HEPES  Streptomycin 5 ml Germany  
   
1.2 g/L NaHCO3) 
    
  h2AR-CHO 0.2 mg/ml G418 200 µl/10 Invitrogen  
         
ml GmbH, 
 
  hM2R-CHO        
            Darmstadt,  
            Germany  
         
  HCMEC Microvascular  Basal medium 500 ml Cellovations  
    Endothelial  cell    ,PELO  
    growth medium Supplement mixture 50 ml Biotech  
    classic mix       GmbH,  
        Antibiotics solution 5 ml Planegg,  
            Germany  
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 HEK293   RPMI 1640   Basal medium  500 ml  PAN  
 (Fibroblasts)      10% fetal bovine   Biotech 
        serum (FBS)   50 ml  GmbH, 
        1% Penicillin/   Aidenbach, 
        Streptomycin  5 ml  Germany 
              
 A10   DMEM(with 4.5  Basal medium  500 ml  Gibco£ 
    g/L glucose and  20% fetal bovine   GmbH, 
    NEAA (non-  serum (FBS)   100 ml  Darmstadt, 
    essential          Germany 
    aminoacids)             
              
 Mesenchymal  F-12K medium   Basal medium  500 ml  PAA  
 Stem Cells     20% fetal calf serum    Laboratories 
 (MSCs)       (FCS)     100 ml  GmbH, 
        1% Penicillin/   Pasching, 
        Streptomycin  5 ml  Austria 
              
 MSCs to DMEMlowglucose  Basal medium  500 ml  PAA  
 Primary   (1g/L)withL-  10% fetal calf serum  50 ml  Laboratories 
 Osteoblast   Glutamine   (FCS)       GmbH, 
 differentiation      Dexamethasone  0.1 µM  Pasching, 
        Ascorbicacid-2-    Austria 
        phosphate   0.05 mM     
        Glycerolphosphates  10 mM     
        Penicillin   100 U/ml    
        Streptomycin  100 g/ml     
                 
3.2.12. Cell lines               
             
 Cell line name   Origin      Source   
 CHO-WT (wild type) Chinese hamster ovary   Kindly provided by Dr. Mohr,
           Bonn, Germany     
            
 h2AR-CHO  Chinese hamsterovary,  Kindly  provided by Dr. Gerd
     transfected with h2AR   Wallukat, Berlin, Germany  
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  hM2R-CHO Chinese Hamster ovary, KindlyprovidedbyDr.Mohr, 
   transfected with hM2R Bonn, Germany  
       
 HCMEC  Human Cerebral AG Blaes, Neurology - Giessen  
   MicrovascularEndothelial   
   cell line    
      
 HEK293  Human fibroblasts cell line AG Blaes, Neurology - Giessen  
      
 U937  Human monocyte cell line AG Blaes, Neurology - Giessen  
      
 A10  Rat smooth muscle cell line AG Blaes, Neurology - Giessen  
      
 Primary Osteoblast Trauma patient ID ZK37 Laboratory of experimental trauma  
 ZK37    surgery, Giessen  
      
 Primary Osteoblast Trauma patient ID ZK48 Laboratory of experimental trauma  
 ZK48    surgery, Giessen  
      
 Primary Osteoblast Trauma patient ID ZK56 Laboratory of experimental trauma  
 ZK56    surgery, Giessen  
      
 Primary Osteoblast Trauma patient ID ZK58 Laboratory of experimental trauma  
 ZK58    surgery, Giessen  
      
 Primary Osteoblast Trauma patient ID ZK59 Laboratory of experimental trauma  
 ZK59    surgery, Giessen  
       
 SAOS-2  Human Osteosarcomacell Laboratory of experimental trauma  
   line  surgery, Giessen  
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3.3.1. Expt. set 1: Determination of pathogenicity of CRPS IgG in immortalized cells 
 
 
 
3.3.1.1. IgG Purification by affinity chromatography 
 
 
 
IgG purification was performed using a HiTrap Protein-G column (HiTrap Protein-G HP). 
Sera from the CRPS patients, HC and RF are diluted to 1:5 in 0.1 M Glycine buffer (pH 9.0). 
For eluting the bound IgG from the Protein-G column, elution buffer is used (0.1 M Glycine 
buffer pH 2.9). The eluted IgG is dialysed against phosphate-buffered saline (PBS, pH 7.4). 
IgG-concentration is determined by nephelometry and stored in aliquots at -20°C at a stock 
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concentration of 3 g/l until used. The working concentration for all the experiments was 
constantly maintained as 12.5 µg/ml. 
 
 
3.3.1.2. Cell culture methods 
 
 
 
Chinese hamster ovary (CHO) cells stably transfected with human muscarinic-2 receptor 
 
(hM2R) or human 2-adrenergic receptors (h2AR) were cultured in DMEM/HAMs F-12 
medium. The medium for transfected cells was supplemented with 63mg/L of Geneticin 
G418. Dr. Gerd Wallukat, Berlin, Germany and Prof. Dr. Mohr, Bonn, Germany generously 
supplied the h2AR-CHO and hM2R-CHO cells respectively. 
 
Human cerebral microvascular endothelial cells (HCMEC) were grown in Human 
Microvascular Endothelial Cell Growth medium. This microvascular endothelial medium 
was enriched with 5% fetal calf serum together with supplements and antibiotics provided by 
the manufacturers. 
 
Human embryonic kidney (HEK293) cells and monocyte cell line U937 were cultured using 
RPMI 1640 nutrient medium. The medium was additionally supplemented with 10% FBS 
and 1% Penicillin/Streptomycin. 
 
Rat smooth muscle (A10) cells were cultured using DMEM (with 4.5 g glucose, Non-
essential amino acids without sodium pyruvate and Glutamine) and suplemented with 20% 
FBS without antibiotic. All cells were grown under standard cell culture conditions (37°C, 
5% CO2). 
 
 
 
3.3.1.3. Expression study by Immunoblotting 
 
 
 
Stably transfected CHO cells overexpressing the 2-adrenergic receptor and M2-muscarinic 
receptor, HCMEC, U937, A10 and HEK293 cells were plated in 6-well plates at a 
concentration of 1x105 cells/ml and examined in western blotting for the expression of 
 
Human Adrenergic 2 receptor (ADRB2) and Muscarinic M2 receptor (CHRM2). Cells were 
lysed using the lysis buffer (Cell signaling technology, Danvers, MA, USA) and the amount 
of protein was estimated by Bradford assay and normalized. Equal amount of protein (60 µg) 
were loaded and separated by 10% SDS-PAGE, transferred (Trans Blot, Semi dry Transfer 
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cell, BioRad) to a nitrocellulose membrane (GE Healthcare, Amersham™ Hybond ECL, 
 
Buckinghamshire, UK) and blocked with 5% BSA for 1hour. The membranes were incubated 
overnight at 4°C with the primary antibodies Anti- 2 Adrenergic receptor antibody; Anti-
Muscarinic Acetylcholine Receptor 2 antibody (31-1D1) (1:500; Abcam, Cambridge, UK). 
Membranes were then incubated for 1 h with goat anti-rabbit and donkey anti-mouse 
secondary antibodies (1:1000, Santa Cruz Biotechnology, CA, USA) and developed using 
SuperSignal West Pico Chemiluminescent Substrate (Thermo scientific, Pierce 
Biotechnology, Rockford, IL, USA) in Fusion FX7 chemiluminescence system (PEQLAB, 
Erlangen, Germany). GAPDH (Santa Cruz Biotechnology, CA, USA) was used as a loading 
control. 
 
 
3.3.1.4. ADRB2 and CHRM2 expression study by flow cytometry 
 
 
 
Stably transfected CHO cells overexpressing the 2-adrenergic receptor and M2-muscarinic 
receptor, HCMEC, U937, A10 and HEK293 cells were plated in 6-well plates at a 
concentration of 1x105 cells/ml and examined in flow cytometry for the expression of Human 
 
Adrenergic 2 receptor (ADRB2) and Muscarinic M2 receptor (CHRM2). Cells were washed 
with 1x PBS and harvested using cell scrapper. Then the cells are plated in 96-well U bottom 
plate. The plate is washed twice by centrifugation at 4000 rpm for 4 mins using 100 µl FACS 
buffer. Then, plates containing cells were incubated with Anti-ADRB2 and Anti-CHRM2 
antibodies for 30 mins at 4°C. After the incubation, cells were washed twice by 
centrifugation at 12000 rpm for 4 mins with 100 µl FACS buffer. The cells were then 
incubated with respective secondary anibodies conjugated with FITC and incubated at 4°C 
for 30 mins. Again the cells are washed by centrifugation using 100 µl FACS buffer and the 
cells are collected in FACS tubes and analysed for relative expression of receptors by flow 
cytometry (FACS Calibur, Beckton Dickinson Biosciences, Heidelberg, Germany) using Cell 
Quest software. The cells are gated with M1, M2 gates and the cells whichever were positive 
for the receptor falls on the M2 gate. The percentage (%) of positivity is determined from the 
histogram statistics table. 
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3.3.1.5. CHRM2 siRNA transfection of HEK293 cells 
 
 
 
HEK293 cells were selected to act as negative control cell line for our experimental 
hypothesis. However, the expression data from western blot revealed the endogenous 
expression of CHRM2 (M2-muscarinic receptor), and few of our CRPS IgG showed 
unspecific binding to the HEK293 cells. Therefore, we knocked down the CHRM2 receptor 
in HEK293 cells using CHRM2 siRNA (Hs_CHRM2_6, Qiagen GmbH, Hilden, Germany). 
The lyophilized siRNA was resuspended with 250 µl RNase-free water (5 nmol scale) as 
mentioned by the manufacturers to get 20 µM stock solution. HEK293 cells were seeded at a 
concentration of 1x106 cells in 6-well plates. The cells were maintained at 37°C in the CO2 
incubator until they became 70% confluent. Lipofectamine® RNAiMAX Reagent (Cat. No. 
#13778-075) and Opti - MEM® I reduced serum medium (Cat. No. #31985-062) was 
purchased from Invitrogen™ by Life technologies, Van Allen Way Carlsbad, CA. 250 µl of 
Opti-MEM® I reduced serum medium was added to dilute 8 µl of Lipofectamine® 
RNAiMAX Reagent and 4 µl of CHRM2 siRNA. Then the diluted CHRM2 siRNA was 
added to diluted Lipofectamine® RNAiMAX Reagent (1:1 ratio). This mixture is vortexed 
and incubated for 20 mins at room temperature to form siRNA-reagent complex. Then 500 µl 
of this siRNA-reagent complex is added to the cells and maintained in an antibiotic free 
medium for 8 h at 37°C in the CO2 incubator. After 8 h, the antibiotic free medium is 
replaced with normal HEK293 nutrient medium mentioned earlier and the transfection 
efficiency is analyzed at 24, 48 and 72 h after transfection by western blotting. CHRM2 
siRNA HEK293 were used as comparative negative control cell to efficiently differentiate the 
binding of CRPS IgG to the HCMEC cells. 
 
 
 
3.3.1.6. Autoantibody binding assay by flow cytometry 
 
 
 
 
Stably transfected CHO cells expressing the 2-adrenergic receptor and M2-muscarinic 
receptor (h2AR-CHO and hM2R-CHO), HCMEC, U937, A10, HEK293 and CHRM2 
siRNA HEK293 cells were examined. Purified IgG (1g/L) was pre-absorbed with wild type 
CHO cells for 24 h in FACS buffer to avoid any unspecific binding. Flow cytometry was 
used to detect surface binding antibodies (Kohr et al., 2011; Kohr et al., 2009). Cells were 
plated into 96-well-plates at a final concentration of 1x105 cells/ml and incubated with the 
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pre-absorbed IgG (final concentration (12.5 µg/ml)) for 30 min at 4°C. Cells were then washed 
with FACS-buffer and incubated with fluorescein isothiocyanate (FITC) labeled anti-human IgG 
secondary antibody (1:75, DAKO), in FACS-buffer for 30 min at 4°C. Cells again were washed 
and analyzed by flow cytometry (FACS Calibur) using cell quest software. Antibodies binding to 
the cell surface are expressed as mean fluorescence intensity (MFI). 
 
 
 
3.3.1.7. Cytotoxicity (Lactate Dehydrogenase, LDH) assay 
 
 
 
Possible cytotoxicity effects of autoantibodies against endothelial (HCMEC), HEK293, U937 
and A10 cells were measured after incubation of the cells with CRPS, radial fracture or 
control-IgG using LDH cytotoxicity assay according to the manufacturer’s instructions 
(Roche applied science, Indianapolis, IN). Cells were seeded in optically clear flat-bottomed 
96 well plates in the concentration of 1x105 cells/ml. 100 Pl of this suspension is filled in the 
96 well plates and kept in culture for 24 h for the cells to adhere in the flat bottom plate. 
Then, old medium was discarded and 200 µl containing IgG (CRPS, RF, HC final 
concentration 12.5 µg/ml) were added and incubated for another 24 h at standard cell culture 
conditions. Assay medium was used as background control, 100 Pl cell suspension and 100 
 
Pl assay medium as low control. To determine the maximum amount of LDH enzyme 
activity, 2% Triton-X 100 was used as high control. After 24 h, the plate was centrifuged at 
250xg for 10 mins. From this, 100 µl supernatant was transferred into new 96-well plates and 
100 µl assay reagent was added and incubated for 30 mins at room temperature in dark. The 
amount of color produced due to the release of LDH enzyme was read in 490 nm in an 
ELISA reader. All the assays were carried out in triplicates, average absorbance values of the 
triplicates were calculated and background control subtracted. Cytotoxicity (%) was 
calculated as follows: 
 
% Cytotoxicity = [(Experimental value – low control value)/ 
 
(High control value – low control value)] x 100 
 
 
 
3.3.1.8. Proliferation (WST-1) assay 
 
 
 
Immortalized cells such as HCMEC, HEK293, U937 and A10 cells cells were seeded in 96 
well plates in a final volume of 100 Pl/well (1x105 cells/ml), maintained in culture until the 
 
 
11-
 
 
cells tightly adhere to the bottom of the plates. Then the old medium was removed and the 
cells were incubated for 24 h with fresh medium containing CRPS, RF or HC-IgG (12.5 
µg/ml). Then 10 Pl of WST-1 reagent (Cell proliferation reagent WST-1, Roche applied 
science, Indianapolis, IN) was added in each well and the assay was carried out as mentioned 
in the instructions provided by the manufacturer. Plates were shaken thoroughly for 1 min on 
a shaker and incubated for 4 h at standard cell culture conditions. The color developed from 
the soluble formazan dye cleaved from the tetrazolium salt WST-1 was measured at an 
absorbance of 420-480 nm in an ELISA reader. 100 Pl of assay medium was taken as blank 
control for measuring the background absorbance. All experiments were carried out in 
triplicates. To calculate proliferation, mean absorbance was calculated and background 
absorbance (medium alone) subtracted from each value. The percentage of specific 
proliferation was quantified using the following calculation: 
 
% Proliferation = (experimental release / spontaneous release) x 100 
 
 
 
3.3.1.9. Real-Time PCR 
 
 
HCMEC cells were plated in 24-well plate at a concentration of 1x105 cells/ml. Cells were 
then incubated at different time points (48 and 72 h) with HC, CRPS and RF IgG (12.5 
µg/ml) and maintained in culture. After 24 h, cells were lysed using lysis buffer provided in 
the total mRNA kit (peqGOLD total RNA kit, Peqlab) and total mRNA was extracted 
according to the instructions given by the manufacturers. Quality of samples (A260/A280 
ratio) was controlled using Nanophotometer (Implen) and quantification was done using the 
same. 1 µg of mRNA was reverse transcribed using the Quantitect reverse transcription 
cDNA synthesis kit (Qiagen) according to the manufacturer’s instructions. qRT-PCR 
reactions were carried out using SYBR Green Master mix (BIORAD) with 5 ng of cDNA. 
Inflammatory mediator gene expression was carried out using StepOne Real-Time PCR 
system (Applied biosciences) according to a standardized protocol. Primers were designed 
Primer-BLAST and the list of primers used for the study is shown in the section 3.2.10 
 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
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3.3.1.10. Secondary messenger pathways 
 
 
 
The expression study in HCMEC cells on treatment with different IgG showed upregulation 
of various inflammatory cytokines in the CRPS IgG treated group. In order to study the 
signaling mechanism activated by the functional autoantibodies, the HCMEC cells were 
plated in 6-well plate and grown as mentioned above. When the cells were adhered and 
monolayer was formed, they were serum starved for 12 h and treated with HC and CRPS IgG 
for 2, 10 and 30 mins. Cells were lysed using the lysis buffer (Cell signaling technology, 
Danvers, MA, USA) and quantified the protein by BCA assay and normalized. Equal amount 
of protein (100 µg) were loaded and separated by 10% SDS-PAGE, transferred (Trans Blot, 
 
Semi dry Transfer cell, BioRad) to a nitrocellulose membrane (GE Healthcare, Amersham™ 
 
Hybond ECL, Buckinghamshire, UK) and blocked with 5% BSA for 1 h. The membranes 
were incubated overnight at 4°C with the primary antibody Anti-P38 (MAPK pathway), Anti-
ERK 1/2, Anti-STAT1, ANTI-AKT (Dilutions and manufacturers are mentioned in table 7). 
Membranes were washed with 1x TBST and incubated for 1 h with goat anti-rabbit and 
donkey anti-mouse secondary antibody (1:1000, Santa Cruz Biotechnology, CA, USA). After 
1 h, the membranes were washed again ith 1x TBST and developed using SuperSignal West 
Pico Chemiluminescent Substrate (Thermo scientific, Pierce Biotechnology, Rockford, IL, 
USA) in Fusion FX7 chemiluminescence system (PEQLAB, Erlangen, Germany). GAPDH 
(1:5000, Santa Cruz Biotechnology, CA, USA) was used as a loading control. 
 
 
3.3.2. Expt. set 2: Pharmacological antagonists assay in endothelial HCMEC cells 
 
 
 
As we are interested to find out the mechanism of functional autoantibodies in vascular and 
bone disturbances we continued our study with endothelial HCMEC cells and primary 
osteoblasts in detail. 
 
 
3.3.2.1. Autoantibody binding assay with AR and M2R antagonists 
 
 
 
HCMEC endothelial cells were cultured at a concentration of 1x106 cells/ml. At 80% 
confluency, the cells were serum starved for 1 h. Later, it was incubated with AR antagonist 
(1 µM of (±)-Propranolol hydrochloride, Sigma-Aldrich, Saint Louis, Missouri, USA) and/or 
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M2R antagonist (1 µM of Atropine, Sigma-Aldrich, Saint Louis, Missouri, USA) in a serum-
free medium for 30 mins at standard cell culture conditions. The cells preincubated with 
antagonists were washed with ice-cold PBS to completely remove the medium containing 
antagonists. Then the HCMEC cells were processed for extracellular flow cytometry 
procedure as described in 3.3.1.6. Later the cells were analyzed in BD FACS Calibur to 
determine the antagonistic activity of the CRPS IgG antibodies. 
 
 
3.3.2.2. LDH assay with AR and M2R antagonists 
 
 
The same procedure mentioned in 3.3.1.7 was repeated in HCMEC cells preincubated with 
 
AR antagonist (1 µM of (±)-Propranolol hydrochloride) and/or M2R antagonist (1 µM of 
Atropine) to check the antagonistic cytotoxicity effects of CRPS IgG after blocking the cells 
with respective blockers. 
 
3.3.2.3. WST-1 assay with AR and M2R antagonists 
 
 
To measure the proliferation rate the protocol 3.3.1.8 was repeated in HCMEC cells 
preincubated with AR antagonist (1 µM of (±)-Propranolol hydrochloride) and/or M2R 
antagonist (1 µM of Atropine). To evaluate whether the antagonists could improve the 
proliferative effects in the HCMEC cells after stimulating with CRPS IgG. 
 
3.3.3. Expt. set 3: Detection of pathogenicity of CRPS IgG in primary osteoblasts 
 
 
3.3.3.1. Cultivation and establishment of primary osteoblasts 
 
 
 
The isolation, cultivation and differentiation of osteoblasts from human bone debris has been 
established in the Laboratory of Experimental trauma surgery, Department of Trauma 
surgery, Justus-Liebig Universität, Giessen and is carried by the following method: the 
incidental drill dust is obtained from the patients (ZK37, ZK48, ZK56, ZK58, ZK59) having 
femur or tibia fracture and undergoing osteosynthesis, and is kept in F-12K medium 
containing 20% fetal calf serum (FCS), 100 U/ml penicillin and 100 g/ml streptomycin. The 
growing cells, which correspond to many characteristics of mesenchymal stem cells, are 
differentiated by the addition of osteogenic differentiation medium (DMEM low glucose with 
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L-glutamine, 10% FCS, 0.1 M dexamethasone, 0.05 mM Ascorbic acid-2-phosphate, 10 
mM-glycerolphosphates, 100 U/ml penicillin and 100 g/ml streptomycin). After 3 weeks of 
incubation in differentiation medium, the cells start showing the typical characteristics of 
osteoblasts (for example, synthesis of collagen-1, mineralization and expression of osteoblast 
markers). 
 
3.3.3.2. Autoantibodies binding to primary osteoblasts by flow cytometry 
 
 
 
Primary osteoblasts ZK37, ZK48, ZK56, ZK58 and ZK59 were cultured in 75 m2 cell culture 
flasks as described in 3.3.3.1. Cells were then processed for extracellular flow cytometry 
staining procedure as described in 3.3.1.6. Later the cells were analyzed in BD FACS Calibur 
to determine the binding efficiency of the CRPS IgG antibodies to the primary osteoblasts. 
 
3.3.2.2. LDH assay in primary osteoblasts 
 
 
 
The primary osteoblasts from different trauma patients (ZK37, ZK48, ZK56, ZK58, ZK59) 
were cultured in 24-well microtiter plates and were treated with HC, CRPS and RF IgG (12.5 
µg/ml) to determine the amount of cytotoxicity. The procedure for cytotoxixity assay was 
followed as mentioned in 3.3.1.7. 
 
3.3.2.3. WST-1 assay in primary osteoblasts 
 
 
 
The primary osteoblasts from different trauma patients (ZK37, ZK48, ZK56, ZK58 and 
ZK59) were cultured in 24-well microtiter plates and were treated with HC, CRPS and RF 
IgG (12.5 µg/ml) to determine the proliferation rate. The procedure for WST-1 proliferation 
assay was followed as mentioned in 3.3.1.8. 
 
 
 
3.3.2.4. Immunofluorescence in primary osteoblasts 
 
 
Annexin-V is a Ca2+-dependent phospholipid-binding protein with high affinity for 
phosphatidylserine (PS). It is used to stain the apoptotic cells, which has altered PS at the 
outer leaflet of the plasma membrane. This staining method also has propidium iodide (PI), 
which helps to stain the DNA, and helps in excluding the necrotic cells and quantifying the 
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Annexin-V stained positive apoptotic cell cluster. Primary osteoblasts from different trauma 
patients ZK37, ZK48, ZK58 were cultured in 24-well plates as described above. When the 
cells were 80% confluent, they were treated with HC, CRPS and RF IgG (12.5 µg/ml) and 
incuabated for 24 h at standard cell culture conditions. After incubation was over, cells were 
washed twice with PBS to completely remove any active debris in the cells. The cells are 
then fixed with 4% paraformaldehyde (PFA) for 20 mins at 4°C. The cells were then washed 
with 1x PBS and then stained with Annexin-V-FLUOS working reagent solution and left in 
4°C for 30 mins. Finally the cells were washed with 1x PBS and observed under fluroscence 
microscope. The cells that were positive for apoptosis could be seen in blebs and were 
stained with Annexin-V and the cells that were stained for both Annexin-V and PI are 
necrotic cells. The plate was imaged and the cells that are positive for apoptosis are counted 
using grid counting method. 
 
3.3.2.5. RT-PCR in primary osteoblasts 
 
 
 
Primary osteoblasts from ZK37, ZK48 and ZK58 were plated in 24-well plate and grown in 
standard cell culture conditions until the cells are completely differentiated to osteoblasts. 
Cells were then incubated for 24 h with HC, CRPS and RF IgG (12.5µg/ml) and maintained 
in culture. After 24 h, cells were lysed using lysis buffer provided in the total mRNA kit 
(peqGOLD total RNA kit, Peqlab) and total mRNA was extracted according to the 
instructions given by the manufacturers. Quality of samples (A260/A280 ratio) was 
controlled using Nanophotometer (Implen). 1 µg of mRNA was reverse transcribed using the 
Quantitect reverse transcription cDNA synthesis kit (Qiagen) according to the manufacturer’s 
instructions. qRT-PCR reactions were carried out using SYBR Green Master mix (BIORAD) 
with 5 ng of cDNA. Osteoblast and osteoclast specific markers gene expression was carried 
out using StepOne Real-Time PCR system (Applied biosciences) according to a standardized 
protocol. Primers were designed Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/). Primers used for the study is shown in section 3.2.10. 
 
 
3.3.2.6. Immunoblotting in primary osteoblasts 
 
 
 
Primary osteoblast from ZK58 was plated in 6-well plate and grown as mentioned above. 
When the cells are completely differentiated to osteoblasts were treated with HC, CRPS and 
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RF IgG for 24 h. Later, cells were lysed using the lysis buffer (Cell signaling technology, 
Danvers, MA, USA) and quantified the protein by BCA assay and normalized. Equal amount 
of protein (90 µg) were loaded and separated by 10% SDS-PAGE, transferred (Trans Blot, 
 
Semi dry Transfer cell, BioRad) to a nitrocellulose membrane (GE Healthcare, Amersham™ 
 
Hybond ECL, Buckinghamshire, UK) and blocked with 5% BSA for 1 h. The membranes 
were incubated overnight at 4°C with the primary antibody Anti-collagen1-D1 (1:1000, R&D 
systems). Membranes were washed with 1x TBST and incubated for 1 h with goat anti-rabbit 
and donkey anti-sheep secondary antibody (1:1000, Santa Cruz Biotechnology, CA, USA). 
After one hour the membranes were washed again with 1x TBST and developed using 
SuperSignal West Pico Chemiluminescent Substrate (Thermo scientific, Pierce 
Biotechnology, Rockford, IL, USA) in Fusion FX7 chemiluminescence system (PEQLAB, 
Erlangen, Germany). GAPDH (1:5000, Santa Cruz Biotechnology, CA, USA) was used as a 
loading control. 
 
3.3.4. Expt. set 4: Intravenous Immunoglobulin (IvIg) study 
 
 
3.3.4.1. Intravenous Immunoglobulin (IvIg) 
 
 
IvIg commercially available as Gamunex® 10% was bought from the Talecris biotherapeutics 
company and dialysed against phosphate-buffered saline (PBS, pH 7.4) to remove the glycine. 25 
mg/ml final concentration of IvIg was used throughout the experiment. 
 
 
3.3.4.2. LDH Assay 
 
 
 
Possible cytotoxicity effects of autoantibodies against endothelial cells (HCMEC), A10 and 
HEK293 were measured after incubation of the cells with HC, CRPS IgG, CRPS IgG + IvIg 
and IvIg alone using LDH-assay kit. The experiment to determine the cytotoxicity after 
incubation with IvIg was carried out as mentioned in 3.3.1.7. 
 
3.3.4.3. WST-1 Assay 
 
 
 
HEK293 and HCMEC were seeded in 96 well plates in a final volume of 100 Pl/well (1x105 
cells/ml), left to adhere for 24 h and then incubated for 24 h with medium containing CRPS 
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IgG, CRPS IgG + IvIg, IvIg alone and HC-IgG (final concentration 1 mg/ml). Then the 
proliferation (WST-1) assay was carried out in the same way as mentioned in 3.3.1.8. 
 
3.3.5. Statistical analysis 
 
 
 
Surface binding of antibodies, cytotoxicity and proliferation assays which has multiple 
groups were analyzed using One-Way ANOVA and a post-test was done using Bonferroni 
post-test or Dunn’s test to compare all pairs of columns after validating the data for normal 
distribution by Kolmogorov-Smirnov test. Surface binding of antibodies that has only two 
groups were analyzed by unpaired t-test or Mann-Whitney U test based on their distribution. 
All data are presented as Mean ± SD. p < 0.05 was considered statistically significant. (* p < 
0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001). Positivity for binding, cytotoxicity and 
proliferation were calculated by the formula (Mean + (Standard deviation X 2.5)) of the 
healthy controls and a line is drawn in graphs. 
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4.1.1. Patient details 
 
 
 
Serum was obtained from 13 clinically defined CRPS patients according to the IASP 
diagnostic criteria (Bruehl et al., 1999; Harden et al., 2007) after informed consent and 
approval from the ethical committee of the Johannes-Gutenberg-University Mainz. Sera of 11 
sex and age matched healthy controls (HC) and 7 radial fracture (RF) patients (who did not 
develop CRPS) served as controls. None of the healthy controls or radial fracture patients had 
a history of hereditary or chronic neuropathic pain. Table 3 shows the detailed clinical and 
immunological data of the CRPS patients. 
 
Table 3: Clinical and epidemiological data of CRPS patients 
 
 
 
Age 49.0 ± 16.0 
Sex 7 female / 6 male 
CRPS I / CRPS II 10/3  
Warm / cold CRPS 11/2  
Pain score Median 4.5 
Spontaneous pain in rest 5 (13) 
Hyperalgesia 5 (10†) 
Affected limb (upper / lower) 10/3 (13) 
Surgery 12 (13) 
Trauma 10 (13) 
Motor impairment* 4 (9†) 
Sensory impairment** 5 (9†) 
Trophic changes 9 (13) 
Time to serum analysis***   
Minimum 4  
Maximum 152  
   
 
CRPS = Complex Regional Pain Syndrome. 
 
* Any paresis in the affected limb, not related to nerve lesion. 
** Any sensory disturbances, not related to nerve lesion. 
*** Time between onset of symptoms and obtaining of serum in weeks. 
 
† Data not available from all patients 
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4.1.2. Determination of ADRB2 and CHRM2 receptor expression 
 
 
Expression study was done to determine cells taken for the study expresses ADRB2 and 
CHRM2 receptors. Relative gene expression of ADRB2 and CHRM2 receptors in CHO 
wild type (WT) and CHO cells overexpressing ADRB2 (h2AR-CHO) and CHRM2 
(hCHRM2) receptors, HCMEC, HEK293 and A10 were analyzed in Quatitative PCR (qPCR, 
Fig. 5A and 5B) and in western blotting (Fig. 5C and 5E). Unexpectedly, the negative control 
cell line HEK293 also expresses the target receptors. This may be due to the endogenously 
expressing CHRM2 in HEK293 cells. To avoid this and to make them proper negative 
control cell line, HEK293 was knocked down with CHRM2 siRNA and the knockdown 
efficiency is measured by western blotting and the result for expression of hM2R is shown 
(Fig. 5D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Expression of ADRB2 and CHRM2 receptors in CHO (WT), h2AR-CHO, hCHRM2-CHO, 
HCMEC, HEK293 and A10 cells. (A) Relative gene expression of ADRB2 in all the cell lines. (B) Relative 
gene expression of CHRM2 in all cell lines. (C) Expression of CHRM2 by western blotting and (D) HEK293 
cells showing knockdown of CHRM2. (E) Expression of ADRB2 in all cell lines by western blotting where 
GAPDH served as housekeeping control gene. 
 
 
"

 
4.1.3. Binding of CRPS IgG to CHO cells overexpressing ADRB2 & CHRM2 
 
 
Surface binding of autoantibodies to CHO cells overexpressing adrenergic, muscarinic 
 
receptors. CRPS IgG showed higher binding to the h2AR-CHO compared to RF and HC 
samples (CRPS 19.05 ± 5.94 vs HC 11.35 ± 2.58 vs RF 7.32 ± 4.41, p < 0.01, Fig. 6A). There 
was also higher binding of CRPS IgG to hM2R-CHO (CRPS 19.19 ± 2.35 vs HC 13.35 ± 
1.67 vs RF 8.12 ± 1.68, each p < 0.001, Fig. 6B). Among all seven RF samples only one 
sample showed positive binding to the h2AR (Fig. 6A). None of the HC or RF IgG showed 
autoantibodies to the M2 receptors (p < 0.001, Fig. 6B). 
 
A B 
  
 
 
Figure 6: Determination of surface binding of HC, CRPS and RF IgG to CHO cells overexpressing ADRB2 
and CHRM2 receptors by flow cytometry. (A) CRPS IgG shows higher binding to the CHO cells 
overexpressing ADRB2 receptor (h2AR-CHO), ANOVA, p<0.01. (B) In CHO-cells overexpressing CHRM2 
receptors (hM2R-CHO), CRPS IgG binds strongly to the surface receptors with a higher statistical significant 
difference. ANOVA, p<0.001. (HC n= 11; CRPS n= 13; RF n= 7) Cut-off marked as horizontal line, was 
determined using the formula mean of the controls + 2.5x standard deviation. HC - healthy control; CRPS - 
complex regional pain syndrome; RF - radial fracture. 
 
4.1.4. Autoantibody detection by FACS with antagonists 
 
 
2 and M2 receptor specific antagonists pre-incubated h2AR-CHO and hM2R-CHO 
cells antagonizes CRPS IgG binding to the ADRB2 and CHRM2 receptors. Binding of 
CRPS IgG to h2AR-CHO and hM2R-CHO cells were significantly reduced on blocking the 
h2AR with AR antagonist, 1 µM of (±)-Propranolol hydrochloride and/or hM2R with M2R 
antagonist, 1 µM of Atropine (CRPS 19.05 ± 5.937 vs CRPS+1 µM (±)-Propranolol 11.75 ± 
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6.738, p < 0.01, Fig. 7A and CRPS 19.19 ± 2.353 vs CRPS+1 µM Atropine 10.65 ± 5.172, p 
 
< 0.001, Fig. 7B). 
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Figure 7: h2AR-CHO and hM2R-CHO cells pre-incubated with AR antagonist, 1 µM of (±)-Propranolol 
hydrochloride or the M2R antagonist, 1 µM of Atropine, significantly reduced the surface binding of 
autoantibodies. (A) 1 µM (±)-Propranolol HCl pre-incubated h2AR-CHO cells blocked the binding of CRPS 
IgG to the CHO cells overexpressing ADRB2 receptor (h2AR-CHO); ANOVA, p < 0.01. (B) 1 µM Atropine 
incubated hM2R-CHO also blocked the binding efficiency of CRPS IgG to CHO cells overexpressing CHRM2 
receptor (hM2R-CHO); ANOVA, p < 0.001. (HC n= 11; CRPS n= 13; RF n= 7) Cut-off marked as horizontal 
line, was determined using the formula mean of the controls + 2.5x standard deviation. 
 
 
 
4.1.5. In vitro flow cytometry assay in immortalized cells 
 
 
In vitro flow cytometry assay shows CRPS IgG binds effectively to the endothelial, 
smooth muscle, fibroblast and osteosarcoma cell lines but not to the CHRM2 
knockdown HEK293 cells. CRPS IgG showed higher binding to the endothelial HCMEC 
cells (CRPS 22.59 ± 5.08 vs HC 14.28 ± 3.57 vs RF 17.66 ± 2.42, p < 0.01, Fig. 8A). In our 
negative control cell line HEK293, three CRPS patients showed positive binding but not 
statistically significant comparing to healthy control but to RF (CRPS 36.62 ± 34.35 vs HC 
20.12 ± 12.03, n.s., CRPS 36.62 ± 34.35 vs RF 7.90 ± 3.12, p < 0.01, Fig. 8B). This 
unspecific binding of CRPS IgG to HEK293 cells may be due to the endogenously 
expressing CHRM2 in HEK293. Therefore, endogenously expressed muscarinic receptors in 
HEK293 cells were knockdown with CHRM2 siRNA. CHRM2 siRNA HEK293 cells 
resulted in blocking of unspecific binding of the CRPS IgG and no statistically significant 
difference was observed between the groups (CRPS 11.29 ± 3.84 vs HC 11.50 ± 2.67 vs RF 
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10.66 ± 3.21, p > 0.05, n.s., Fig. 8B). Besides this CRPS IgG also showed higher binding to 
the smooth muscle cells, A10 (CRPS 33.73 ± 19.75 vs HC 14.78 ± 4.70, p < 0.05 and CRPS 
33.73 ± 19.75 vs RF 32.23 ± 14.03, p > 0.05, n.s., Fig. 8C) and Osteosarcoma, SAOS-2 cell 
lines (CRPS 9.17 ± 2.68 vs HC 6.32 ± 1.73, p < 0.05 and CRPS 9.17 ± 2.68 vs RF 7.70 ± 
1.40, p > 0.05, n.s., Fig. 8D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Binding of functionally active autoantibodies against ADRB2 and CHRM2 receptors in (A) 
Endothelial HCMEC (B) HEK293 with and without knockdown of CHRM2 receptor (C) A10 smooth muscle 
and (D) SAOS-2 cells. To all the above-mentioned cells, CRPS IgG shows increased binding compared to the 
healthy control (HC) and radial fracture (RF) patients. ANOVA, p < 0.001 in HCMEC and p < 0.05 in A10 and 
SAOS-2 cells. To avoid unspecific binding of CHRM2 receptors in HEK293, cells were knockdown using 
siRNA. When knockdown, the unspecific binding has been ruled out as shown above in (B). (HC n= 11; CRPS 
n= 13; RF n= 7) Cut-off marked as horizontal line, was determined using the formula mean of the controls + 
2.5x standard deviation. 
 
4.1.6. Cytotoxicity assay in immortalized cells 
 
 
CRPS IgG causes higher cytotoxicity in HCMEC, A10 and SAOS-2 cells but not in the 
negative control HEK293 cell line. The cytotoxic effect of HC, CRPS and RF IgG on 
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HCMEC cells were analyzed in HCMEC, HEK293, A10 and SAOS-2 cell lines. After 
incubating HCMEC cells with different IgG, CRPS IgG showed higher cytotoxic effects 
compared to both HC and RF IgG (CRPS 14.90 ± 5.645 vs HC 1.494 ± 3.871, p < 0.01; 
CRPS 14.90 ± 5.645 vs RF -12.81 ± 2.716, p < 0.001, Fig. 9A). A10 Smooth muscle cell and 
negative control cell line HEK293 did not show any statistically significant cytotoxic effects 
between the HC and CRPS IgG (p > 0.05, n.s.) but with RF IgG (p < 0.05, Fig. 9B and 9C 
respectively). SAOS-2 cells also showed higher cytotoxic effects between the groups (CRPS 
21.70 ± 10.12 vs HC 1.904 ± 8.655, p < 0.05; CRPS 21.70 ± 10.12 vs RF 44.87 ± 15.52, p < 
0.05, Fig. 9D). 
 
 
Figure 9: CRPS IgG mediated cytotoxicity in HCMEC, HEK293, A10 and SAOS-2 cells. (A) CRPS IgG 
stimulated HCMEC cells showed severe cytotoxic effects of about 80%, p < 0.01 compared to the HC and RF 
controls. (B) Negative control cell line HEK293 showed equal cytotoxicity in both HC and CRPS groups, p > 
0.05, n.s., leaving a significant difference between the CRPS and RF groups, p < 0.05. (C) Equal cytotoxic 
effects were observed in A10 cells between the groups and (D) CRPS IgG stimulation resulted in higher 
cytotoxic effect in SAOS-2 cells compared to HC, p < 0.05 but RF IgG had still more compared to the CRPS 
group, p < 0.05. (HC n= 11; CRPS n= 13; RF n= 7) Cut-off marked as horizontal line, was determined using the 
formula mean of the controls + 2.5x standard deviation. 
 
""

 
4.1.7. Proliferation assay in immortalized cells. 
 
 
CRPS IgG severely reduces proliferation of endothelial, smooth muscle and SAOS-2 
 
cells. HCMEC, A10, SAOS-2 and HEK293 cells were stimulated with HC, RF, and CRPS 
IgG for 24 h. And 1 h incubation with WST-1 proliferation reagent revealed that HCMEC 
cells treated with CRPS IgG has less proliferation rate compared to the HC (CRPS 11.55 ± 
3.14 vs HC 16.74 ± 0.546, p < 0.001, Fig. 6A; CRPS 11.55 ± 3.14 vs RF 16.94 ± 0.40, p < 
0.001), without statistical difference between HC and RF samples (p > 0.05, n.s., Fig. 10A). 
Similar effects were also observed in A10 and SAOS-2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: CRPS IgG mediated proliferation effects in endothelial, smooth muscle, SAOS-2 and HEK293 cells. 
 
(A) CRPS IgG stimulated HCMEC cells showed severe decrease in proliferation compared to the HC and RF 
controls, p < 0.001 each. (B) Negative control cell line HEK293 showed equal cytotoxicity in all three groups, p 
 
< 0.05, n.s.(C) Proliferation was drastically reduced in CRPS IgG stimulated A10 cells compared to the HC, p 
 
< 0.001, leaving the RF IgG stimulated group with even lesser proliferation rates. (D) SAOS-2 cells stimulated 
with various IgG showed significant decrease in CRPS IgG stimulated group compared to HC, p < 0.05 with no 
significant difference between the RF IgG and CRPS group, p < 0.05. (HC n= 11; CRPS n= 13; RF n= 7) Cut-
off marked as horizontal line, was determined using the formula mean of the controls + 2.5x standard deviation. 
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In A10 cells, the CRPS IgG stimulated group had very less proliferating cells compared to 
that of the HC and RF IgG stimulated groups (CRPS 0.30 ± 0.05 vs HC 0.450 ± 0.03, p < 
0.001; CRPS 0.30 ± 0.05 vs RF 0.25 ± 0.04, p < 0.05, Fig. 10C). SAOS-2 cells stimulated 
with CRPS IgG also has lesser proliferation rate comparing to the other two groups (CRPS - 
21.40 ± 16.82 vs HC 7.619 ± 12.94, p < 0.05; CRPS -21.40 ± 16.82 vs RF -50.24 ± 13.46, p 
> 0.05, n.s., Fig. 10D). HEK293 negative control cells had no statistically significant 
difference in proliferation between the different IgG stimulated groups (p > 0.05, n.s., Fig. 
10B). 
 
4.1.8. 2 and M2 receptor specific antagonists study 
 
 
2 and M2 receptor specific antagonists pre-incubated HCMEC endothelial cells 
antagonizes CRPS IgG binding to the target receptors. To understand whether the 
blocking of ADRB2 and CHRM2 receptors with their respective antagonists would 
antagonize the binding efficiency thereby decrease the cytotoxic effects and recover the 
proliferation rate caused by the CRPS IgG in the endothelial cells, endothelial cells were pre-
incubated with 1 µM (±)-Propranolol HCl or 1 µM Atropine and stimulated with CRPS IgG 
and analyzed for functional assays. 
 
CRPS IgG showed significant decrease in binding to surface receptors in AR and M2R 
antagonists pre-incubated HCMEC cells (CRPS 22.59 ± 5.08 vs CRPS + 1 µM (±)-
Propranolol HCl 15.66 ± 4.64, p < 0.01, vs CRPS + 1 µM Atropine 12.97 ± 3.91, p < 0.001, 
Fig. 11A). 
 
Cytotoxicity caused by CRPS IgG was not prevented when the HCMEC endothelial cells 
were preincubated with AR and M2R antagonists. Although there is a reduction in the 
cytotoxic effects in the AR and M2R antagonists pre-incubated HCMEC cells, we couldn’t 
find a statistically significant difference between the groups (CRPS 14.90 ± 5.64 vs CRPS+1 
µM (±)-Propranolol HCl 8.84 ± 7.66 vs CRPS+1 µM Atropine 9.88 ± 7.24, n.s., Fig. 11B). 
 
On treating CRPS IgG with the HCMEC cells that were pretreated with AR and M2R 
antagonists, the proliferating property of the cells increased to a statistically significant level 
(CRPS 11.55 ± 3.14 vs CRPS+1 µM (±)-Propranolol HCl 13.95 ± 2.02, p < 0.01 and CRPS 
11.55 ± 3.14 vs CRPS+1 µM Atropine 14.58 ± 1.74, p < 0.001, Fig. 11C). 
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Figure 11: Antagonizing effects of CRPS IgG by pre-incubating the HCMEC cells with AR and M2R 
antagonists (1 µM (±)-Propranolol HCl and 1 µM Atropine respectively). (A) CRPS IgG showed significant 
decrease in binding to surface receptors in AR (p < 0.01) and M2R antagonists (p < 0.001) pre-incubated 
HCMEC cells. (B) Cytotoxicity caused by CRPS IgG was not prevented when the HCMEC endothelial cells 
were preincubated with AR and M2R antagonists, p > 0.05, n.s. (C) The proliferating property was recovered 
(almost equal to the HC IgG treated group) on treating CRPS IgG with the HCMEC cells that were pretreated 
with AR, p < 0.05 and M2R antagonists, p < 0.01. (HC n= 11; CRPS n= 13; RF n= 7). Cut-off marked as 
horizontal line, was determined using the formula mean of the controls + 2.5x standard deviation. 
 
4.1.9. Gene expression of pro-inflammatory cytokines 
 
 
Expressions of pro-inflammatory cytokines were elevated in CRPS IgG stimulated 
endothelial HCMEC cells. To investigate the study in gene level, HCMEC endothelial cells 
were taken to study in detail as the vascular disturbances and inflammation in CRPS patients 
are yet to be understood. HCMEC cells were stimulated with HC, CRPS and RF IgG for 24 h 
and the relative gene expression of endothelial specific pro-inflammatory cytokines such as 
ICAM-1 (CD54), VCAM-1, MCP-1, TGF-E1 and BMP-2 were analyzed. CRPS IgG 
stimulated HCMEC cells showed higher expression of pro-inflammatory cytokines such as 
ICAM-1 (p < 0.001, Fig. 12A), VCAM-1 (p < 0.05, Fig. 12B) and MCP-1 (p < 0.01, Fig. 
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12C). Simultaneously, CRPS IgG treated HCMEC cells showed significant decrease in the 
expression of proliferation and differentiation related genes such as TGF-E1 (p < 0.001, Fig. 
12D) and BMP-2 (p < 0.05, Fig. 12E). All data normalized to GAPDH, blank is set to 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Expression of endothelial specific pro-inflammatory cytokines and differentiation related genes in 
HCMEC cells after stimulating with HC, CRPS and RF IgG. CRPS IgG stimulated group had higher expression 
of pro-inflammatory cytokines (A) Intercellular adhesion molecule – 1, ICAM-1/CD54, p < 0.001 (B) Vascular 
cell adhesion molecule – 1, VCAM-1, p < 0.05 (C) Monocyte chemoattractant protein – 1, MCP-1, p < 0.01. 
CRPS IgG stimulated group had decreased expression of proliferation and cell differentiation related genes (D) 
Transforming growth factor - E1, TGF-E1, p < 0.001 (E) Bone morphogenic protein – 2, BMP-2, p < 0.05. (HC 
n= 11; CRPS n= 13; RF n= 7, all data normalized to GAPDH, blank is set to 1). 
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4.1.7. Secondary messenger pathways 
 
 
Regulation of secondary messengers in HCMEC cells after treating with HC and CRPS 
 
IgG. In order to analyze the effects of CRPS IgG on inflammation mediating MAPK 
signaling pathways in HCMEC endothelial cells, we treated them with HC and CRPS IgG. 
Interestingly, CRPS IgG treated HCMEC cells promoted a marked 3-4 fold increase in 
ERK1/2 activation that was not observed in samples from healthy controls (HC), phospho 
ERK1/2 (pERK1/2, p < 0.001, Fig. 13A, 13B and 13C). Similar elevated levels of pP38 (3-
fold increase), the major MAPK family member were also observed in CRPS IgG treated 
HCMEC cells, phospho P38 (pP38, p < 0.001, Fig. 14A, 14B and 14C). In order to confirm 
the inflammatory effects caused by the CRPS IgG in the HCMEC cells, we also screened the 
levels of pSTAT-1, a well-known pro-inflammatory mediator and we observed a 4-5 fold 
increase that was not observed in HC IgG treated HCMEC cells, phospho STAT-1 (pSTAT-
1/ Y701, p < 0.001, Fig. 15A, 15B and 15C). Additionally, CRPS IgG treated HCMEC cells 
showed significant down-regulation in proliferation and differentiation protein phospho AKT 
(pAKT, p < 0.001, Fig. 16A, 16B and 16C). All data were quantified using BIO-ID software 
(the graph is placed adjacent to the blots) and normalized to their respective total proteins 
such as total STAT-1, total P38, total AKT and total ERK 1/2, blank is set to 100. 
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Figure 13: CRPS IgG are potent stimulators of ERK 1/2 pathway in HCMEC cells. A) HCMEC cells were 
incubated for 5 mins with IgGs (12.5 µg/ml) obtained from different HC and CRPS patients and ERK 1/2 
activation were assessed using specific anti-phospho ERK antibodies (pERK 1/2). Blots were reprobed for total 
cellular ERK 1/2 levels to normalize the results. B) Data are represented as fold-stimulation of ERK activity 
over basal conditions (without any IgG stimulation, considered as 100), and are represented as mean ± SE of 3 
independent experiments. C) ERK stimulation by CRPS patients IgG was significantly higher (p < 0.001) when 
compared to the healthy controls (Unpaired t-test). Representative blots are shown in the panels. (HC n= 10; 
CRPS n= 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: CRPS IgG are effective activators of phospho P38 MAPK pathway proteins in HCMEC endothelial 
cells. A) HCMEC cells were incubated for 5 mins with IgGs (12.5 µg/ml) obtained from different HC and 
CRPS patients and pP38 activation was assessed using specific anti-phospho P38 antibodies (pP38). Blots were 
reprobed for total cellular P38 levels to normalize the results. B) Data are represented as fold-stimulation of P38 
activity over basal conditions (without any IgG stimulation, considered as 100), and are represented as mean ± 
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SE of 3 independent experiments. C) P38 stimulation by CRPS patients IgG was significantly higher (p < 0.001) 
when compared to the healthy controls (Unpaired t-test). (HC n= 9; CRPS n= 12) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: CRPS IgG are effective activators of pSTAT-1 (a pro-inflammatory mediating protein) in HCMEC 
cells. A) HCMEC cells were incubated for 5 mins with IgGs (12.5 µg/ml) obtained from different HC and 
CRPS patients and pSTAT-1 activation were assessed using specific anti-phospho STAT-1 antibodies (pSTAT-
1). Blots were reprobed for total cellular STAT-1 levels to normalize the results. B) Data are represented as 
fold-stimulation of STAT activity over basal conditions (without any IgG stimulation, considered as 100), and 
are represented as mean ± SE of 3 independent experiments. C) ERK stimulation by CRPS patients IgG was 
significantly higher (p < 0.001) when compared to the healthy controls (Unpaired t-test). (HC n= 9; CRPS n= 
12). 
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Figure 16: CRPS IgG are effective activators of pAKT (cell differentiation and survival mediator) in HCMEC 
cells. A) HCMEC cells were incubated for 5 mins with IgGs (12.5 µg/ml) obtained from different HC and 
CRPS patients and pAKT activation was assessed using specific anti-phospho AKT antibodies (pAKT). Blots 
were reprobed for total cellular AKT levels to normalize the results. B) Data are represented as fold-stimulation 
of AKT activity over basal conditions (without any IgG stimulation, considered as 100), and are represented as 
mean ± SE of 3 independent experiments. C) ERK stimulation by CRPS patients IgG was significantly higher (p 
< 0.001) when compared to the healthy controls (Unpaired t-test). (HC n= 9; CRPS n= 12). 
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4.2.1. Autoantibody detection by FACS in primary osteoblasts 
 
 
Primary osteoblasts differentiated from MSCs of different trauma surgery patients were 
incubated with HC, CRPS IgG and analyzed in flow cytometry for the surface binding 
autoantibodies. Primary osteoblasts such as ZK22, ZK34 and ZK38 showed no statistical 
significant difference in binding between the HC and CRPS IgG stimulated groups (p > 0.05, 
n.s., Fig 17A, 17B and 17C respectively). CRPS IgG binds efficiently to the ZK37, ZK48 and 
ZK58 primary osteoblasts surface receptors (p < 0.05, n.s., Fig 17D, 17E and 17F 
respectively). (HC n= 10; CRPS n= 10). 
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Figure 17: Determination of surface binding autoantibodies in primary osteoblasts differentiated from 
mesenchymal stem cells (MSCs). (A, B, C) ZK22, ZK34, ZK38 patient’s derived osteoblasts did not show 
statistically significant difference between the groups in binding of functionally active autoantibodies, p > 0.05, 
n.s. (D, E, F) Whereas CRPS IgG stimulated group showed increased amount of functionally active 
autoantibodies in ZK37, ZK48 and ZK58 osteoblasts, p < 0.05. (HC n= 11; CRPS n= 13) Horizontal line is the 
mean of the samples within the groups. 
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4.2.2. Functional assays in primary osteoblasts 
 
 
 
Primary osteoblasts from three patients (ZK37, ZK48, and ZK58) who showed positivity for 
surface autoantibody binding were taken to carry out the further cell based functional assays 
and gene level expression studies. Cell based assays such as cytotoxicity and proliferation 
assays were carried out in all these three different osteoblasts. All three primary osteoblasts 
were stained for Annexin-V and propidium iodide in immunofluorescence to understand in 
detail whether the cytotoxic effects are consequences of apoptosis or necrosis. Later, 
osteoblasts specific markers expressions were analyzed in qPCR. Finally, immunoblotting 
was done for quantification of collagen-1, an osteoblast specific marker in these primary 
osteoblasts. 
 
 
4.2.2.1. Cytotoxicity assay 
 
 
 
To determine whether the patient’s cells which were positive for binding leads to higher 
cytotoxicity, Lactate Dehydrogenase (LDH) release assay was carried out in all the three 
patient osteoblast cells. The cytotoxic effect of HC, CRPS and RF IgG on ZK37, ZK48 and 
ZK58 osteoblasts were analyzed. After incubating ZK37, ZK48 and ZK58 cells with different 
HC, CRPS and RF IgG, CRPS IgG caused higher cytotoxic effects in ZK37 (HC vs CRPS, p 
< 0.05 and CRPS vs RF p > 0.05, n.s., Fig 18A) and also in ZK58 (HC vs CRPS, p < 0.001 
and CRPS vs RF p > 0.05, n.s., Fig. 18C). On the other hand, ZK48 did not show any 
statistically significant difference in their cytotoxicity. All the three groups in ZK48 showed 
equal cytotoxic effects (HC vs CRPS vs RF, p > 0.05, n.s., Fig 18B). (HC n= 10; CRPS n= 
10; RF n= 7) 
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Figure 18: Cytotoxicity assay of primary osteoblasts after incubating different IgG for 24 h. (A) ZK37 
osteoblast cells after stimulation showed higher cytotoxicity in CRPS IgG stimulated group, p < 0.05 showing 
no difference between CRPS vs RF group, p > 0.05, n.s. (B) All the three different IgGs caused equal 
cytotoxicity in ZK48 cells, HC vs CRPS vs RF, p > 0.05, n.s. (C) ZK58 cells had higher cytotoxicity in CRPS 
IgG treated cells, p < 0.001 with no significant difference in RF group, p > 0.05, n.s. (HC n= 10; CRPS n= 10; 
RF n= 7) Cut-off marked as horizontal line, was determined using the formula mean of the controls + 2.5x 
standard deviation. 
 
 
4.2.2.2. Proliferation assay 
 
 
 
The proliferation rate of primary osteoblasts (ZK37, ZK48 and ZK58) after stimulation of 
HC, CRPS and RF IgG for 24 h was analyzed. After incubating ZK37, ZK48 and ZK58 cells 
with different HC, CRPS and RF IgG, CRPS IgG treated cells had very less proliferation rate 
in all three different osteoblasts. ZK37 showed decreased proliferation property in CRPS IgG 
stimulated group comparing to other two groups (HC vs CRPS, p < 0.05 and CRPS vs RF p > 
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0.05, n.s., Fig 19A). CRPS IgG treated ZK48 also had very less proliferating effect (HC vs 
CRPS, p < 0.001 and CRPS vs RF p > 0.05, n.s., Fig 19B). In the ZK58 cells the proliferating 
rate was drastically decreased in both CRPS and RF IgG treated groups (HC vs CRPS, p < 
0.001 and CRPS vs RF p < 0.001, Fig 19C). (HC n= 10; CRPS n= 10; RF n= 7). 
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Figure 19: Proliferation assay in primary osteoblasts. In all the three different osteoblasts, CRPS IgG mediated 
a significant decrease in proliferating property. (A) ZK37, p < 0.05 (B) ZK48, p < 0.001 and (C) ZK58, p < 
0.001. (HC n= 10; CRPS n= 10; RF n= 7) Cut-off marked as horizontal line, was determined using the formula 
mean of the controls + 2.5x standard deviation. 
 
 
4.2.3. Immunofluorescence staining of primary osteoblasts 
 
 
 
Primary osteoblasts showed increased necrosis by stimulation of CRPS IgG. The 
 
cytotoxic effects caused by the CRPS IgG were studied further in immunofluorescence to 
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understand whether the cytotoxicity is due to apoptosis or necrosis. For this reason, the 
primary osteoblasts were incubated with HC, CRPS and RF IgG for 24 h and stained with 
Annexin-V FLUOS staining kit. Annexin-V-FLUOS binds in a Ca2+- dependent manner to 
negatively charged phospholipid surfaces, and shows high specificity for phosphatidylserine 
(PS). Therefore, it stains apoptotic and necrotic cells. Since necrotic cells also expose PS 
because of lost membrane integrity, propidium iodide is utilized as a DNA stain to 
distinguish necrotic cells from Annexin-V-labeled cell clusters. 
 
Cells with no treatment were considered as blank (Fig 20A), 1 µM digitonin (Fig 20B) and 
staurosporine (Fig 20C) were used as apoptotic and necrotic positive controls respectively. 
When the cells were stimulated with HC, CRPS and RF IgG for 24 h in all the three different 
(ZK37, ZK48 and ZK58) osteoblasts, CRPS IgG stimulated cells showed completely 
compromised cytoplasm and allowing the propidium iodide to stain the leaky nucleus. 
Quantification of number of cells positive for propidium iodide was done by randomly 
choosing three fields in each image of every sample and the average was taken and plotted in 
bar graph. In ZK37, comparing to HC and RF, the CRPS IgG mediated a very high necrotic 
effect. The quantification graph is shown, (p < 0.001, Fig 20D, E, F, G). ZK48 also shows 
higher number of necrotic cells in CRPS IgG stimulated cells, (p < 0.05, Fig 20H, I, J, K). 
ZK58 showed compromised cytoplasm in both CRPS and RF IgG treated groups comparing 
to the HC, (p < 0.05, Fig 20L, M, N, O). (HC n= 10; CRPS n= 10; RF n= 7). 
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Figure 20: Quantification of apoptotic and necrotic cells by Annexin-V FLUOS immunofluorescence staining. 
In all the three different osteoblasts, CRPS IgG mediated a significantly increased number of propidium iodide 
positive necrotic cells. Images were taken at 10x objective with the scale of 200 µm and the inner square is the 
same representative image taken in 40x objective. (A) Blank, (B) 1 µM Digitonin (necrotic positive control), (C) 
1µM Staurosporine (apoptotic positive control), ZK37 (D) HC, (E) CRPS, (F) RF IgG treated cells stained for 
Annexin – V and propidium iodide, (G) Quantification bar graph of ZK37 to show the number of propidium 
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iodide positive cells, p < 0.001. ZK48 (H) HC, (I) CRPS, (J) RF IgG treated cells stained for Annexin – V and 
propidium iodide, (K) Quantification bar graph of ZK48 to show the number of propidium iodide positive cells, 
p < 0.01. ZK58 (L) HC, (M) CRPS, (N) RF IgG treated cells stained for Annexin – V and propidium iodide, (O) 
Quantification bar graph of ZK58 to show the number of propidium iodide positive cells, p < 0.01. (HC n= 10; 
CRPS n= 10; RF n= 7). 
 
 
4.2.4. Gene expression study of osteoblast markers 
 
 
 
Decreased expression of osteoblast specific markers in primary osteoblasts might 
explain the reason for patients with CRPS developing bone-related disturbances. 
Primary osteoblasts differentiated from MSCs were treated with HC, CRPS and RF IgG for 
24 h and the relative gene expression of osteoblast specific markers such as Collagen, type I, 
alpha-1 or COL1A1 (Col-1), dickkopf-1 (DKK-1), osteocalcin or bone gamma-
carboxyglutamic acid-containing protein (BGLAP) and alkaline phosphatase (ALP) were 
analyzed. An irregularity in the expression of these genes alters the proper bone building and 
regulating processes. Primary osteoblasts (ZK37, ZK48 and ZK58) were incubated with HC, 
CRPS and RF IgG for 24 h and the expression of the above-mentioned genes were studied. 
ZK37 showed statistically significant decrease in all osteoblast specific markers in CRPS IgG 
treated group, ALP (p < 0.01, fig 21A), Col-1 (p < 0.05, fig 21B), osteocalcin (p < 0.05, fig 
21C) and DKK-1 (p < 0.05, fig 21D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
&9

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Relative mRNA expression of osteoblast specific markers in ZK37 primary osteoblast. ZK37 
showed statistically significant decrease in all osteoblast specific markers in CRPS IgG treated group. 
Expression of the genes are shown in the figure (A) ALP (p < 0.01), (B) Col-1 (p < 0.05), (C) osteocalcin (p < 
0.05) and (D) DKK-1 (p < 0.05). (HC n= 10; CRPS n= 10; RF n= 7). Experiments are carried out in triplicates 
and the average of each sample is plotted in the graph. All data normalized to GAPDH and blank is set to 1. 
 
 
 
On the other hand, ZK48 did not show statistically significant difference in ALP (p > 0.05, 
n.s., fig 22A) and DKK-1 (p > 0.05, n.s., fig 22D) between the different groups but with a 
significant decrease in Col-1 and osteocalcin (p < 0.05 each, fig 22B and 22C) in CRPS IgG 
treated group. Additionally, the RF IgG treated group in ZK48 had higher expression of 
DKK-1 (p < 0.05, fig 22D). Finally, ZK58 when treated with different IgG did not alter the 
expression of ALP (p > 0.05, n.s., fig 23A) but had a statistically significant decrease in the 
expression of Col-1 (p < 0.01, fig 23B), osteocalcin (p < 0.001, fig 23C) and DKK-1 (p < 
0.05, fig 23D) in the CRPS IgG stimulated group leaving no significant difference between 
the CRPS and RF IgG stimulated groups. (HC n= 10; CRPS n= 10; RF n= 7). Experiments 
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are carried out in triplicates and the average of each sample is plotted in the graph. All data 
 
normalized to housekeeping gene GAPDH and blank is set to 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Relative mRNA expression of osteoblast specific markers in ZK48 primary osteoblast. ZK48 did not 
show statistically significant difference in (A) ALP (p > 0.05, n.s.) and (D) DKK-1 (p > 0.05, n.s.) between the 
different groups but with a significant decrease in (B) Col-1 and (C) osteocalcin (p < 0.05 each) in CRPS IgG 
treated group. Additionally, the RF IgG treated group in ZK48 had higher expression of (D) DKK-1 (p < 0.05). 
(HC n= 10; CRPS n= 10; RF n= 7). All data normalized to GAPDH and blank is set to 1. Experiments are 
carried out in triplicates and the average of each sample is plotted in the graph. 
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Figure 23: Relative mRNA expression of osteoblast specific markers in ZK58 primary osteoblast. ZK58 treated 
with different IgG did not alter the expression of (A) ALP (p > 0.05, n.s.) but had a statistically significant 
decrease in the expression of (B) Col-1 (p < 0.01), (C) osteocalcin (p < 0.001) and (D) DKK-1 (p < 0.05) in the 
CRPS IgG stimulated group leaving no significant difference between the CRPS and RF IgG stimulated groups. 
(HC n= 10; CRPS n= 10; RF n= 7). All data normalized to GAPDH and blank is set to 1. Experiments are 
carried out in triplicates and the average of each sample is plotted in the graph. 
 
 
4.2.5. Immunoblotting of Collagen-1 in primary osteoblasts 
 
 
 
ZK37 (primary osteoblasts) were treated with HC, CRPS and RF IgG for 24hrs and collagen 
protein expression was analyzed by immunoblotting (Fig. 24A). Four randomly selected IgGs 
from each group were incubated with ZK37 (primary osteoblasts) and the cell lysate was 
analyzed in immunoblotting for collagen-1 (col-1) protein. We found that CRPS IgG treated 
ZK37 showed significantly reduced levels of col-1 (p < 0.001, Fig. 24B) comparing to the 
HC and RF IgG treated groups. Reduced levels of col-1 in CRPS IgG treated primary 
osteoblasts clearly explains that CRPS IgG has a pathological role in the col-1 expression and 
synthesis. 
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Figure 24: Immunoblotting of Collagen-1 in ZK37. A) CRPS IgG has the ability to reduce the collagen-1 
protein level in primary osteoblasts. B) Quantification graph showing the ZK37 treated with CRPS IgG had 
significantly reduced levels of Col-1 (p < 0.001) comparing to the HC and RF IgG treated groups. 
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Recently, IvIg is used to treat many autoimmune and inflammatory diseases including CRPS. 
In this queue, studies are carried out in the view to identify the mechanism of IvIg in treating 
the autoimmune diseases but their complexity in behavior and the signaling pathway 
underlying is not yet clearly understood. Our 13 CRPS patients IgG reported that when 
endothelial cells incubated with CRPS IgG, higher cytotoxicity is observed compared to the 
healthy control. Captivatingly, when the cells were incubated with CRPS IgG + IvIg fractions 
at 100mg/ml substantially reduced the cytotoxicity levels in HCMEC, HEK 293 and A10 
cells. However, the proliferation rate of the cells that were incubated with CRPS + IvIg 
fractions does not show any statistically significant difference between the groups. Thus, we 
were interested to study the effect of IvIg along with CRPS patients IgG in various other cell 
types, which are believed to contribute vascular, bone and connective tissue metabolism and 
thereby lead to local trophic changes. 
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4.3.1. IvIg mediated cytotoxicity 
 
 
 
The cytotoxic effect of HC, CRPS IgG, IvIg alone and CRPS IgG + IvIg on HCMEC and 
HEK293 cells were analyzed. After incubating HCMEC with IgG, CRPS IgG incubated cells 
showed higher cytotoxic effects compared with both, HC (p < 0.001) and CRPS IgG + IvIg 
(p < 0.001, Fig. 25A). Incubation of HEK293 with the HC and CRPS IgG-fractions showed 
no difference between HC and CRPS (n.s) but a significant decrease in cytotoxicity was seen 
in cells treated with CRPS IgG + IvIg (p < 0.01, Fig. 25B). A10 cells also showed reduced 
cytotoxic effects when treated with IvIg along with the CRPS IgG (p < 0.001, fig 25C). 2% 
Triton X-100 was used as positive control and all the experiments were repeated in 
triplicates. 
 
 
 
A B  
    
 C   
    
 
 
 
Figure 25: IvIg mediated cytotoxic effects of HC, CRPS and CRPS + IvIg to human microvascular endothelial 
cells HCMEC, HEK293 and A10 cells. CRPS IgG when treated with endothelial HCMEC cells induced higher 
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cytotoxicity compared to HC (p < 0.001) and CRPS + IvIg (p < 0.001). CRPS - IgG did not induce any 
significant cytotoxicity compared to HC (p > 0.05) in the HEK293 cells, but a significantly reduced cytotoxicity 
is observed in the CRPS + IvIg group (p < 0.01). A10 cells when treated with IvIg along with CRPS IgG 
showed less cytotoxic effects compared to CRPS IgG alone group (p < 0.001). 
 
 
4.3.2. IvIg mediated proliferation 
 
 
 
After four hours treatment with WST-1 proliferation reagent, HCMEC incubated with CRPS 
IgG showed less proliferation when compared to the healthy control (p < 0.001), Fig. 26A), 
without difference between other two pairs (CRPS vs CRPS + IvIg and HC vs CRPS + IvIg, 
p > 0.05). No statistically significant difference in proliferation rates was observed in 
HEK293 cells between the HC and CRPS groups but a statistically significant decrease of 
proliferation is observed in the CRPS + IvIg samples when compared to other two groups (p 
< 0.001), Fig 26B). In A10 cells, CRPS + IvIg treated group showed a statistically significant 
decrease in the proliferation rate when compared to HC and CRPS IgG treated groups (p < 
0.001, Fig 26C). 
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Figure 26: IvIg mediated proliferation rate of HCMEC, HEK293 and A10 cells after incubation with HC, 
CRPS and CRPS + IvIg is measured after 4 h treatment with WST-1 proliferation reagent. (A) HCMEC showed 
less proliferation when incubated with CRPS IgG compared to HC, (p < 0.01), whereas no difference is seen 
between CRPS and CRPS+IvIg (p>0.05). (B) HEK293 showed no significant effects between the HC and CRPS 
IgG however a statistically higher difference is seen between the CRPS and CRPS+IvIg groups (p < 0.001). (C) 
A10 cells showed a statistically significant decrease in proliferation in the CRPS + IvIg treated group, (p < 
0.001). 
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CRPS is a multifactorial disease, including different pathogenic mechanisms. Neurogenic 
inflammation following trauma is the main peripheral mechanism in CRPS. However, central 
sensitization and genetic factors are also involved in the pathogenesis of the disease. In the 
recent years, an involvement of the immune system has been suspected to be an important 
factor in CRPS development. In this thesis, I have studied the involvement of autoantibodies 
in this process and their effects on various cell types affected in CRPS. This study is an 
approach to gain the deeper insight in the immunological part of pathophysiology of CRPS. 
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CRPS is a painful, debilitating, and often-chronic condition characterized by various sensory, 
motor and vascular disturbances. Despite many years of study, current treatments are limited 
due to lack of understanding of the underlying mechanisms. Limited studies are available that 
attempted to explain the molecular level changes in gene expression supporting the 
nociceptive sensitization commonly observed in CRPS limbs, or how those changes might 
evolve over time (Gallagher et al., 2013). Vascular abnormalities were one of the commonly 
observed autonomic disturbances in CRPS patients. Vascular breakdown or leakage could be 
responsible for various symptoms in CRPS patients, such as edema and temperature 
regulation disturbances. Breakdown of immunologic self-tolerance, development of 
autoantibodies to 2AR and M2R receptors were also shown to be considerable elements in 
adult CRPS cases (Kohr et al. 2011) and could be involved in the development of autonomic 
symptoms in CRPS. These autoantibodies progress to initiate the autoimmune-mediated 
neuro-inflammatory response. 
 
Substantial evidence has been shown that CRPS is a neurogenic inflammatory disorder with a 
probable autoimmune component in many individuals (Blaes et al., 2007; Goebel, 2011; 
Goebel et al., 2011). Kohr et al. described in their study of adult CRPS patients, that 90% of 
the cohort had autoantibodies to either the 2AR (Beta-2 adrenergic receptor) or to the M2R 
(muscarinic acetylcholine receptor) (Kohr et al., 2011). Similarly, our results also show that 
83% of total patients taken in the study had autoantibodies against surface epitopes of 2AR 
and/or M2R. Only one out of 7 patients with radial fracture and none of the controls showed 
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positive binding to the CHO-cells overexpressing the ADRB2 receptors and none to the 
CHRM2 receptor, indicating that the autoantibodies are disease-specific. Besides, blocking 
the receptors with their specific antagonists also blocked binding of autoantibodies to these 
receptors to about 80%. 
 
 
In our study, the endothelial cell line HCMEC expresses target receptors, 2AR and M2R. 
We could demonstrate autoantibody binding of CRPS sera to HCMEC and this binding 
affects the cell proliferation and led to an increased cytotoxicity. 
 
The expression of pro-inflammatory cytokines was elevated in the CRPS-IgG treated 
HCMEC endothelial cells. These cells showed elevated levels of adhesion molecules such as 
ICAM-1, VCAM-1 and the chemokine MCP-1 (CCL2), when incubated with CRPS-IgG. 
Cytokines play a major role in recruiting monocytes, neutrophils, and lymphocytes, as well as 
in inducing chemotaxis through the activation of G-protein-coupled receptors that also 
involves adhesion molecules and glycosaminoglycans. Monocyte chemoattractant protein-1 
(MCP-1/CCL2) is one of the key chemokines that regulate migration and infiltration of 
monocytes/macrophages (Flugel et al., 2001). Both the protein CCL2 and its receptor CCR2 
were demonstrated to be induced and involved in pathology of various diseases such as 
AIDS, autoimmune diseases like multiple sclerosis, psoriasis, RA, pulmonary and vascular 
disorders. Immunological surveillance of tissues, as well as the generation of pathological 
inflammatory response requires migration of monocytes from the blood stream across the 
vascular endothelium. CCL2 secreted in or injected into skin arrives in the draining lymph 
nodes where it can be presented on the surface of high endothelial venules for recruitment of 
lymphocytes. MCP-1 expression is usually in peak at day 3 post-operation but their up-
regulated levels could be observed for up to several weeks after operation. According to a 
study by Flügel and collegues (Flugel et al., 2001), neuronal MCP-1 and its corresponding 
receptor CCR2 is up-regulated in response to remote nerve injury but they could not spot any 
differential levels of RANTES and IP10. In many peripheral nerve injury models, neither 
IFN-J nor STAT-1 tyrosine was phosphorylated. The increased expression of various pro-
inflammatory mediators in HCMEC endothelial cells after treating with CRPS IgG drives us 
to speculate that it could be a possible reason for the endothelial dysfunction and vascular 
disturbances in CRPS patients. 
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Additionally, we found that these autoantibodies are able to potently induce phosphorylation 
of the inflammatory cascades such as ERK 1/2, STAT-1 and P38 MAPK pathways by 
activating 2AR in HCMEC cells. To analyze this effect in detail, we performed 
immunoblotting by stimulating the IgGs from CRPS patients and HC in HCMEC cells. ERK 
stimulation was significantly up-regulated in the endothelial HCMEC cells when treated with 
CRPS IgG when compared to healthy control IgG. To confirm that the ERK stimulation leads 
to inflammation we also analyzed the major inflammation mediating signaling cascades such 
as P38 MAPK and STAT-1 and found that P38 and STAT-1 were also up-regulated in the 
CRPS IgG treated HCMEC cells. P38 phosphorylation is responsible for the production and 
signal transduction of chemokines and cytokines. All these data suggests that CRPS IgG 
binding to target receptors (ADRB2 and CHRM2) play important roles in activating the 
inflammatory mediating cascades and in sustaining the vicious cycle of inflammatory 
response. On the other hand AKT-1 phosphorylation is significantly reduced in HCMEC cells 
stimulated with CRPS IgG comparing to the healthy controls. The PI3K/Akt pathway is 
necessary for several key endothelial cell (EC) functions, including cell growth, migration, 
survival, and vascular tone. Decreased levels of AKT in CRPS IgG stimulated endothelial 
cells could disturb all the above-mentioned functions, which may explain the vascular 
dysfunction in CRPS patients. 
 
Antiendothelial autoantibodies have been described in a variety of diseases, for example 
Susac syndrome (SS) (Magro et al., 2011), atherosclerosis (Varela et al., 2011), systemic 
vasculitis (Miura et al., 2012) and undifferentiated connective tissue diseases (Lage et al., 
2012). Interestingly, most studies could not identify the underlying target antigens. However, 
functional effects of these autoantibodies have been found. A specific study highlights that 
AECA (Anti-endothelial cell antibodies) positive sera from Behcet’s disease patients induced 
elevated levels of ICAM-1 expression and increased phosphorylation of ERK 1/2 in human 
dermal microvascular endothelial cells (Lee et al., 2002). Another study showed that P38 
MAPK activation contributes to autoimmune renal injury in mice (Iwata et al., 2003). AECA 
plays an important role in mediating connective disease associated with pulmonary arterial 
hypertension. It has been shown that IgG purified from the sera of AECA positive could 
increase the expression of ICAM-1 and other chemokines in cultured endothelial cells (Li et 
al., 2010; Liu et al., 2014). 
 
Apart from this many other cascades might be involved that mediate the local inflammation 
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in the affected limb. Reports suggest that vascular inflammation can be detected by enhanced 
circulating IL-6 produced by the activated inflammatory cells within the vessel wall (Brasier, 
2010; Steyers and Miller, 2014). IL-6 production, in turn induces the expression of various 
inflammatory mediators such as C-reactive protein (CRP) and angiotensinogen (Ridker et al., 
2002). In our study, we found that IL-6 expression is not significantly increased in CRPS-IgG 
treated cells. A variety of pro-inflammatory agonists activate inflammation in the smooth 
muscle cells, fibroblasts and endothelial cells, all of which could be involved in the local 
inflammation in CRPS. The activation pathway is via the NF-B transcription factor 
including TNF-, local and systemic inflammatory mediators such as CD40 ligands. More 
downstream this could induce the expression of monocyte adhesion proteins including 
VCAM-1 and ICAM-1 (Brasier, 2010). Our detailed study about the expression of these 
adhesion molecules in the vascular endothelial cells (HCMEC) after treatment with CRPS 
IgG explains that these antibodies could act as possible activators that drive the chemotaxis 
and activation of vascular inflammation in CRPS. 
 
We included the radial fracture (RF) group as a comparative disease control group to 
understand whether the autoantibody against the surface receptors residing in the trauma 
patients in the early stage or they develop later in the disease condition. Unfortunately, we 
couldn’t get consistent results in the binding and functional assays, which left us unable to 
derive a clear explanation. One possible reason could be, in RF, the IgG itself could have 
undergone some trauma-induced modifications such as glycosylation that produced varying 
results in the binding and cell based assays in immortalized cells. Recent evidence from 
several independent model systems suggests that IgG glycosylation is critical for the 
immunomodulatory activity of IgG (Bohm et al., 2014). In a pregnancy cohort study, it is 
shown that N-linked glycosylation of the Fc fragment of IgG changes during the pathological 
and physiological events and strongly influence antibody mediated inflammatory properties 
(Bondt et al., 2014). 
 
Activation of one of the target receptors (2AR) leads to the down regulation of density of 
receptor and suppresses the immune reactions such as down regulation of cytokine 
production, suppression of IL-2 receptor expression and inhibit lymphocyte proliferation 
(Feldman et al., 1987). One major effect of stimulation of 2AR in the downstream of the 
signaling cascade is the elevation of cyclic AMP level. There are various sources of studies 
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that explain the immunosuppressive effect of beta-2 agonists may be due to the elevation of 
cyclic AMP level. Considering beta-adrenergic (2AR) receptors and muscarinic M2 
receptors as target for the autoantibodies from CRPS patients we did block these receptors by 
their specific blockers (AR and M2R antagonists, 1 µM (±)-Propranolol HCl and 1 µM 
Atropine respectively) in the vascular endothelial cells. We found that blocking the receptors 
significantly reduced the surface binding of CRPS IgG to the HCMEC cells and also 
increased the proliferation effect in these cells. Although there was reduced cytotoxic effect 
after blocking the receptors it was not statistically significant in the CRPS IgG treated 
HCMEC cells. This may be due to a different regulation of proliferation and cytotoxicity by 
the autoantibodies and needs further investigation. 
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Beta-adrenergic receptors (2AR) are expressed in many cell types, including osteoblasts, 
cardiomyocytes, lymphocytes, skeletal muscle, smooth muscle and endothelial cells. The 
receptor can activate various signaling pathways in these cells. All the main effect of 
sympathetic neurons on bone cells such as norepinephrine release during bone remodeling is 
mainly mediated by 2AR expressed by osteoblasts. Recent studies have shown that the 
involvement of muscarinic acetylcholine receptors (mAChRs) plays an important role in cell 
proliferation and ALP activity in osteoblasts (Liu et al., 2011; Sato et al., 2010). The 
expression of our target receptors on the osteoblast cells helps us to study the effects our 
CRPS IgG on primary osteoblasts derived from different patients. Bone metabolism in CRPS 
is substantially impaired, leading to severe demineralization in the affected limb in about 
40% of the patients. We focused in our study on the effects of the binding of autoantibodies 
from CRPS patients to osteoblasts expressing the receptor and the probable activating or 
blocking effect of the autoantibodies. 
 
We were interested to study the bone-related disturbances in CRPS patients in two ways: 1) 
to study the pathophysiological role of various CRPS IgG in osteoblasts and 2) to track the 
functional differences that might alter the disease complexity in individuals by using 
osteoblasts from various trauma patients (ZK22, ZK34, ZK38, ZK41, ZK37, ZK48 and 
ZK58). We used reaming debris collected from different trauma patients and differentiated to 
primary osteoblasts. When treated with HC or CRPS IgG, amongst seven different trauma 
 
'
"
 
 
patients derived osteoblasts three of them did not show statistically significant binding 
between the groups but the other four showed higher binding of the CRPS IgG to osteoblasts. 
From this we have taken three trauma patients (ZK37, ZK48 and ZK58) derived osteoblasts 
that showed higher binding in flow cytometry for further examination. In cell based 
functional assays such as cytotoxicity CRPS IgG treated osteoblasts (ZK37 and ZK58) had 
significantly increased cytotoxicity compared to the HC group. Although in ZK48, CRPS 
IgG treated group showed higher binding of functionally active antibodies to the surface 
receptors they did not show any statistical difference in the cytotoxicity assay between the 
groups. Additionally, CRPS IgG treated ZK48 had less proliferation property. CRPS IgG by 
binding to the surface receptors expressed by the bone cells mediates severe necrosis that is 
almost similar to the effect of 10 µM digitonin, which is a potential necrosis mediator. All 
three different trauma patient derived osteoblasts showed increased necrotic effect in the 
CRPS IgG treated group. The main reason of doing immunofluorescence staining with 
Annexin-V in these primary osteoblasts was to differentiate whether the cytotoxicity caused 
by CRPS IgG were due to necrosis or apoptosis. It was clear from our results that all the three 
different osteoblasts on treatment with CRPS IgG had severe necrosis and not apoptosis. This 
could be another possible explanation for CRPS patients with bone related disturbances such 
as osteoporosis. 
 
In addition to all the above-mentioned observations in primary osteoblasts, we also 
investigated the expression of various osteoblast specific markers at mRNA and protein level. 
Osteoblast specific markers such as collagen - 1, alkaline phosphatase, osteocalcin, dickkopf-
1 were studied in all the three different trauma patient derived osteoblasts after treating them 
with different IgG for 24 h. All the three different osteoblasts showed individually different 
expression pattern of these markers at baseline. COL1A1 gene is responsible in encoding the 
alpha-1 type I collagen protein. This protein strengthens and supports many tissues in the 
body, including bone and skin. Mutation or abnormal polymorphism of this gene can result in 
various disorders such as osteogenesis imperfecta type I to type IV and is also involved in the 
development of osteoporosis. In our study, all the three different patient derived osteoblasts, 
when treated with CRPS IgG, had statistically significant decrease in the expression of 
collagen-1 both in mRNA level and protein level. 
 
Alkaline phosphatase (ALP) is another important enzyme important for normal calcification 
of bone. It is considered as one of the main bone turnover marker that mediates the formation 
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of bone. In our study containing different trauma patient derived osteoblasts, we couldn’t 
observe any statistically significant difference in their expression between the three IgG 
groups (CRPS and control groups) in ZK48 and ZK58 whereas a significant decrease in the 
ALP-1 expression is seen in CRPS IgG treated ZK37 osteoblasts. This variable expression by 
individuals is yet to be studied in detail. Apart from this other important bone formation 
markers such as BGLAP or osteocalcin (OC) and dickkopf-1 (DKK-1), a WNT signaling 
mediator showed also a reduced expression in the osteoblasts with the CRPS IgG. Reduced 
expression of these bone formation markers could be a possible explanation for CRPS 
patients who have been reported for reduced BMD (bone mineral density) and patchy 
osteoporosis (Kumar et al., 2001; Moriwaki et al., 1997). Chronic constriction injury (CCI) is 
a model for CRPS (Type 2), in which the sciatic nerve in rats will be ligated. Several studies 
showed, that injured limbs of animals with CCI in the sciatic nerve had reduced BMD and 
bone mineral content as compared to the contralateral side of the animal (Suyama et al., 
2002). Other studies also reported the evidence of osteoporosis in CRPS patients and an 
improvement of pain using bisphosphonates, a osteoporosis drug, has been described in four 
randomized controlled studies in CRPS patients (Abe et al., 2011). 
 
A clear thread that bridges the vascular and bone related disturbances in CRPS with an 
inflammatory effect of autoantibodies against the target receptors (2AR and M2R) was not 
yet explained elsewhere. However, few studies explain the beta-adrenergic receptor (2AR) 
signaling in osteoblasts might contribute to the catabolic effect of glucocorticoids in bone and 
leads to osteoclastogenesis-mediated bone loss (Ma et al., 2011). During normal bone 
remodeling, norepinephrine released in bones by sympathetic neurons suppresses bone 
formation and promotes bone resorption (Elefteriou et al., 2005; Takeda et al., 2002). 
Another study showed that stimulating the 2AR by its agonists such as isoproterenol or 
norepinephrine stimulates osteoclastogenesis and inhibits osteoblast proliferation. This 
process is mediated in bone cells by stimulating the beta-adrenergic receptors (2AR) 
expressed by osteoblasts (Fu et al., 2005; Katayama et al., 2006). This observation would 
support our hypothesis, that an agonistic 2AR antibody could contribute to the osteoporosis 
seen in CRPS. Few in vivo studies have demonstrated pharmacological blockers of E-blocker 
or specific deletion of ADRB2 gene increased the bone mass. On the other hand, some 
studies showed that 2AR agonists increased the bone resorption instead of increasing the 
bone mass (Bonnet et al., 2007). 
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Various studies have shown that 2AR signaling is regulated by exposure to catecholamines 
and its expression at the cell membrane to enable cells to maintain stringent control over 
hormonal or neuropeptide responsiveness (Mak et al., 1995). Endogenous hormones like 
glucocorticoids and thyroid hormones also regulate 2AR signaling and the response of cells 
to catecholamines. Glucocorticoids can counteract the down-regulation of Adr2 expression 
induced by 2AR agonists in vivo (Hadcock et al., 1989) and can increase Adr2 expression 
in multiple cell types (Cheng et al., 1980; Collins et al., 1988; Nakada et al., 1989; Norris et 
al., 1987). 
 
To have a more standardized model we used the SAOS-2 osteosarcoma cells and the A10 
smooth muscle cells and determined the surface binding of autoantibodies and their 
functional effects in the cells after treating them with CRPS IgG and controls. The IgG from 
CRPS patients showed statistically higher binding to the cell surface of these cells. Moreover, 
SAOS-2 osteosarcoma cells had higher cytotoxicity and very less proliferation activity when 
exposed to CRPS IgG. Obviously, cells that express our target receptors (either 2AR or 
M2R or both) had higher binding of IgG from CRPS patients to the cell surface. The antibody 
binding is activating the signaling mechanism that is followed through these receptors. 
Interestingly, one study shows specific antibodies against human cultured chondrosarcoma 
(HCS2/8) and osteosarcoma (SAOS-2) cells in the serum of patients with osteoarthritis 
(Kuboki et al., 1999). However, the underlying autoantigen in these cases has never been 
determined. The 2AR pathway was extensively studied in various cell types regarding its 
expression, activation and its response elements (Cornett et al., 1998; Feve et al., 1990; 
Rodan and Rodan, 1986; Takahashi and Iizuka, 1991; Zajac et al., 1986). In ROS17/2.8 
osteosarcoma cells, glucocorticoids increased PTH and isoproterenol-mediated activation of 
adenylate cyclase activity (Rodan and Rodan, 1986). Together these observations suggest that 
antibody-mediated increased signaling activity of 2AR in HCMEC endothelial, A10 smooth 
muscle, SAOS-2 and also in primary osteoblasts (ZK37, ZK48 and ZK58) can extend the 
responsiveness of these cells to the local trophic disturbances, bone catabolic and 
antianabolic effect of sympathetic neurons. 
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In the recent years, high-dose intravenous immunoglobulin (IvIg) is used for the treatment of 
autoimmune and inflammatory diseases. Currently few autoimmune diseases were effectively 
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treated by IvIg therapy, for example, Guillian-Barre syndrome, Kawasaki disease and chronic 
inflammatory demyelinating polyneuropathy (CIDP) (Durandy et al., 2005; Nimmerjahn and 
Ravetch, 2008). Despite numerous studies demonstrating efficacy, the precise mode of action 
is unclear. Paradoxically, IvIg can exert both pro-inflammatory and anti-inflammatory 
activities based upon its concentration. On one hand, low-dose IvIg requires complement 
activation or binding of the Fc fragment of IgG to IgG-specific receptors (FcJR) and elicits a 
pro-inflammatory activity on innate immune effector cells. On the other hand, when 
administered in high concentrations, IvIg has anti-inflammatory activities (Durandy et al., 
2009). The exact mechanism of action of IvIg as an anti-inflammatory agent remains to be 
elucidated fully. Some studies have proposed that the anti-inflammatory activity of IvIg can 
be attributed to a minor species of immunoglobulins (IgGs) that is modified with terminal 
sialic acids on their Fc-linked glycans. It has also been proposed that these Fc-sialylated IgGs 
engage a unique receptor on macrophages that, in turn, leads to the up-regulation of an 
inhibitory FcJ receptor, thereby protecting against autoantibody-mediated pathology 
(Nimmerjahn and Ravetch, 2007). 
 
There are very few studies that have shown the efficacy of IvIg treatment for CRPS. Medlin 
et al. (Medlin et al., 2013) treated a young patient with high-dose IvIg who developed CRPS 
secondary to a sciatic compression and found a favorable outcome in this particular patient. 
Another study attempted to explain the mechanism and mode of action of IvIg and its 
immunosuppressive activity in Experimental Autoimmune Myasthenia Gravis (EAMG) by 
isolating IvIg a disease-specific suppressive fraction. This IvIg were passed through columns 
of IgG from rats with experimental autoimmune MG (EAMG) or from MG patients and 
found that these fractions resulted in depletion of the suppressive activity of IVIG on rat 
EAMG whereas the minute amounts of IgG fractions eluted from the EAMG- or MG-specific 
columns retained the immunosuppressive activity of IVIG (Fuchs et al., 2008; Zhu et al., 
2006). Apart from this, few other studies after having used IvIg in their RCTs proposed that 
high-dose IvIg could be a treatment option for CRPS (Goebel et al., 2010; Goebel and Blaes, 
2013; Goebel et al., 2013). Additionally, our group has also shown that IvIg inhibits the 
BAFF (B-cell activating factor) production in chronic inflammatory demyelinating 
polyneuropathy (CIDP) and explained BAFF as a new target for IvIg in CIDP treatment 
(Bick et al., 2013). Considering all these previous studies and the anti-inflammatory 
properties of IvIg, we also studied the role of IvIg (Intravenous immunoglobulin) in IgG 
mediated damage of endothelial, fibroblast and smooth muscle cells in CRPS. We could 
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observe CRPS IgG was able to induce higher cytotoxic effects in these cells and the effect 
was reversed with the administration of IvIg along with the CRPS IgG. A similar effect have 
been described in literature that shows that administration of IvIg has reversed the cytotoxic 
effects of endothelial cells and prevents them from inflammation (Nimmerjahn and Ravetch, 
2007, 2008). Although, the proliferation property did not gain any improvement, IvIg 
administration did recover the cells from being damaged. There are hopes as well as doubts 
in using IvIg in treating CRPS, because it is very expensive and relatively less percentage of 
patients were benefited by the treatment as compared to the randomized trials who received 
ketamine, magnesium or tadalafil (Birklein and Sommer, 2010; Collins et al., 2009; 
Groeneweg et al., 2008; Schwartzman et al., 2009). The exact mechanism of action of IvIg 
has to be studied in detail in order to explain how they suppress the inflammation in CRPS 
patients. 
 
Understanding the complex symptoms in the clinical progression of CRPS also requires 
understanding about the modeling of the immunologic and integrative physiology. Achieving 
a cellular and molecular understanding of the clinical progression of CRPS is a complex 
mechanism. Distressed neurons and glial cells release numerous factors into the parenchyma 
of the central nervous system from the bloodstream, which stimulate the extravasation of 
leukocytes and autoantibodies (Watkins et al., 2007). When 2AR and M2R autoantibodies 
exudate from blood vessels along with leukocytes and complement proteins, serious 
neuroinflammatory consequences would be expected to arise (Cooper and Clark, 2013). 
Several studies witnessed that remote immune activation play a potential role in evoking 
trans-synaptic microglial activation in numerous neurological disorders (Banati, 2003). 
Considering these previous literatures as evidence for the remote neuroimmune activation, 
possibilities are there that the functionally active autoantibodies against 2AR and M2R 
could also recruit similar activation. These results strongly support the autoimmune 
hypothesis in CRPS. Binding of these functionally active autoantibodies from CRPS IgG to 
the target receptors (2AR and/or M2R) might trigger various transcription factors 
responsible for inflammation, cell proliferation, differentiation, survival or programmed to 
cell death. 
 
In conclusion, our study highlights the role of autoantibodies against the 2AR and M2R in 
the CRPS pathophysiology. It also reveals how the participating cells expressing 2AR or 
M2R were influenced not only by the local neurogenic inflammation, but also by 
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autoantibody-mediated effects. However, the complete role of these autoantibodies against 
needs to be elucidated in detail. A simplified pictorial representation of my finding is shown 
in Fig. 27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Pictorial representation of findings originated from this thesis. IgG from CRPS patients binds 
effectively to cells expressing 2AR or M2R receptors and has pathogenic effects in CRPS patients. 
 
 
One crucial question is the time and the reason of this autoantibody response. The antibodies 
could possibly be present before the trauma occurs and could become pathogenic by a 
dramatically changed receptor expression induced by the trauma. Surprisingly, our radial 
fracture control group also had varying results that we failed to explain in detail. Although, a 
general mechanism that explains the complexity of complex regional pain syndrome is 
missing, this study is first step to approach the disease with a deeper molecular insight. An 
elaborative study of beta-adrenergic receptors and the muscarinic receptors and their 
signaling mechanism in this disease condition may extend our knowledge on the subtle 
interaction between the receptor autoantibodies and the immune system. 
 
 
 
 
 
''
&&(
 
 
 
7$!118
 
 
CRPS is a neuropathic pain syndrome with severe trophic disturbances, which develops in 
about 0.2 - 0.5% of all trauma patients following a limb trauma or surgery. In Germany with 
about 4000-8000 new cases expected per year, about 30-40% of patients show a chronic 
course, often leading to loss of ability to use the affected limb. The main symptoms include a 
severe neuropathic pain syndrome, accompanied by severe trophic disturbances such as 
edema, increased skin temperature, impaired regulation of blood flow and osteoporosis. 
These autonomic / trophic changes indicate disturbances in the vascular regulation, the 
connective tissue and bone metabolism. Although neurogenic inflammation in the affected 
limb is an important factor of the disease, the actual trigger factors, in addition to the trauma, 
are not yet known. As a new factor we were able to show autoimmune process against 
autonomic nerve fibers as well as against neuronal cell surface epitopes. This includes 
functionally active autoantibodies against the ADRB2 (2 adrenergic receptor) and CHRM2 
(muscarinic M2 receptor). An expression of our identified target receptors (ADRB2 and 
CHRM2) on endothelial cells, smooth muscle, osteosarcoma cells and osteoblasts have been 
described in previous literature and confirmed by us through the expression studies. 
 
Initially, sera obtained from CRPS patients showed higher binding to the CHO-cells 
overexpressing the ADRB2 and CHRM2 receptors. Blocking the target receptors with their 
specific antagonists reversed the binding effects. As our main interest in this study is to 
address the inflammatory mechanisms in vascular endothelial cells and bone related issues in 
CRPS, we did further detailed study with HCMEC cells and primary osteoblasts. We were 
able to find that 86% of patients showed effective binding to the target receptors expressed in 
endothelial HCMEC cells. Binding of these autoantibodies lead to higher cytotoxic effects in 
the HCMEC cells and decreased proliferation rate compared to controls. Additionally, 
expression studies proved that CRPS IgG incubation to vascular endothelial cells stimulated 
highly elevated levels of pro-inflammatory mediators and adhesion molecules such as ICAM-
1, VCAM-1 and MCP-1. We were also able to show that CRPS IgG is a potent stimulator of 
ERK 1/2, P38 MAPK and STAT-1 pathways. TGF-E1 (transforming growth factor, a key 
regulator of cell growth, cell proliferation, cell differentiation) and BMP-2 (bone 
morphogenic protein, key regulator of TGF beta signaling pathway) levels were reduced 
which could be a possible explanation for less proliferation rate of HCMEC cells. This was 
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confirmed by the reduced levels of AKT phosphorylation in HCMEC cells that were 
stimulated with CRPS IgG. 
 
Secondly, our results showed that CRPS IgG binding to primary osteoblasts from different 
patients varies in their binding, cytotoxic and proliferation properties. Surprisingly, all three 
different osteoblasts incubated with CRPS IgG showed higher necrosis but not apoptosis, 
which explains that these IgG has damaging pathogenic effects on the bone cells. 
Additionally, we were also able to find that CRPS IgG incubated for 24hrs with the primary 
osteoblasts lead to reduced expression levels of osteoblast-specific markers such as Col-1, 
DKK-1, ALP and BGLAP/osteocalcin. All these markers are essential for bone 
mineralization and differentiation process. Reduced expression of these markers explains a 
possibility for poor bone formation and osteoporotic events in these patients. 
 
Finally, we also studied the mechanism of the immunomodulator IvIg on the CRPS IgG-
induced effects on HCMEC, HEK293 and A10 cells and observed CRPS IgG when incubated 
along with IvIg had reduced cytotoxic effects in these cells. Although there was not much 
improvement were observed in their proliferation rates. Therefore, IvIg if studied in detail 
about their mechanism of action, can be used as a potent drug for treating CRPS. One 
possible mechanism may be the occurrence of idiotypic antibodies in the IvIg preparations as 
described in the treatment of other autoimmune diseases. 
 
The detection of functionally active autoantibodies in serum samples from CRPS patients 
against autonomic nervous structures, adrenergic and muscarinic receptor suggests an 
autoimmune participation as an important pathogenic factor in the pathophysiology of CRPS. 
Thus, our findings contribute to an understanding of the molecular mechanisms that are 
involved in inflammation and local trophic changes and possibly drive a way for new 
treatment strategies focusing on the immune system. 
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Das komplex-regionale Schmerzsyndrom (CRPS) ist ein neuropathisches Schmerzsyndrom, 
welches sich in etwa 0.2-0.5% aller Traumapatienten nach einem Extremitätentrauma, 
seltener nach Operationen entwickelt. In Deutschland gibt es etwa 4000-8000 neue 
Erkrankungen pro Jahr. Etwa 30-40% der Patienten entwickeln ein chronisches Stadium, das 
oft zur Gebrauchsunfähigkeit der betroffenen Gliedmaße führt. Die wichtigsten Symptome 
sind ein schwerer neuropathischer Schmerz in der distalen Extremität, sowie trophische und 
autonome Störungen, wie Ödem, veränderte Hauttemperatur, livide Hautverfärbung und 
langfristig eine Osteoporose. Diese Symptome weisen auf eine Störung der Gefäßregulation, 
des Bindegewebes und des Knochenstoffwechsels hin. Eine lokale neurogene Entzündung 
nach einem Trauma ist ein wichtiger Faktor in der Pathogenese der Erkrankung, der 
eigentliche Auslöser dieses Prozesses ist jedoch unklar. Wir identifizierten kürzlich 
Autoantikörper als einen weiteren pathogenen Faktor bei Patienten mit CRPS, welche gegen 
den muskarinischen M2 Acetylcholinrezeptor (M2R) sowie gegen den adrenergen 2 
Rezeptor (2AR) gerichtet sind. Eine Expression dieser beiden Rezeptoren auf verschiedenen 
 
Zelltypen, wie Endothelzellen, glatte Muskelzellen, Osteoblasten und Osteosarkomzellen 
wurde beschrieben und zu Beginn dieser Studie von uns bestätigt. 
 
Seren von CRPS Patienten zeigten eine höhere Bindung an M2R- oder 2AR-transfizierte 
CHO Zellen im Vergleich zu Kontroll-Seren. Pharmakologische Blockade der Rezeptoren 
verhindert die Bindung der Antikörper. Unser Hauptinteresse galt nun der Frage, ob 
Antikörper gegen diese Rezeptoren an andere (nicht-neuronale) Zelltypen binden und ob 
dadurch funktionelle Effekte ausgelöst werden. Diese Effekte wurden im Detail bei 
endothelialen Zellen und Osteoblasten untersucht. 86% der CRPS Patienten zeigten Bindung 
an die endotheliale Zelllinie HCMEC und diese Antikörper induzierten eine höhere 
Zytotoxizität und eine reduzierte Proliferationsrate im Vergleich zu verschiedenen 
Kontrollen. Inkubation mit CRPS-IgG führte dabei zu einer erhöhten Expression von 
proinflammatorischen Mediatoren und Adhäsionsmolekülen, wie ICAM-1, VCAM-1 und 
MCP-1. Eine vermehrte Expression oder Sekretion von IL-6 konnten wir nicht beobachten. 
Im weiteren konnte gezeigt werden, dass CRPS-IgG zu einer Phosphorylierung von ERK-1/2, 
P38 MAPK und STAT-1 führt. Transforming growth factor (TGF)-1 (wichtiger Regulator 
der Zellproliferation und differenzierung) und bone morphogenetic protein (BMP)-2 
 
*
9&&
 
 
(wichtiger Regulator des TGF-1 pathway) waren dabei reduziert, was die 
 
Proliferationshemmung der HCMEC Zellen durch CRPS-IgG erklären könnte. Passend dazu 
war die Phosphorylierung von AKT reduziert. 
 
In einem weiteren Schritt konnte nachgewiesen werden, dass CRPS IgG an primäre 
Osteoblasten bindet und in diesen Zellen zu einer erhöhten Zytotoxizität führt, wobei hier 
keine apoptotischen Zellen, sondern eine gesteigerte Nekrose nachgewiesen wurde. 
Weiterhin konnten wir zeigen, dass CRPS-IgG die Expression von Osteoblastenmarkern 
(Col-1, DKK-1, ALP und BGLAP/osteocalcin) reduziert. Diese Proteine sind essenziell für 
eine ausreichende Osteoblastenaktivität und eine entsprechende Mineralisierung des 
Knochens. Eine Antikörper-medierte Expressionsreduktion könnte die lokale Osteoporose bei 
CRPS Patienten erklären. 
 
Zuletzt untersuchten wir, ob die pathogenen Effekte der CRPS-IgG Fraktionen durch die 
immunmodulatorisch wirkende intravenöse Immunglobuline (IVIg, gepooltes Spender-IgG) 
beeinflusst werden können. Dabei zeigte sich eine Reduktion des zytotoxischen Effekts, 
weniger jedoch des antiproliferativen Effekts. Ein möglicher Mechanismus dieses Effekts 
könnte durch das Auftreten antiidiotypischer Antikörper (gegen die entsprechenden 
Autoantikörper) in den IVIg-Fraktionen erklärt werden. 
 
Die Detektion funktionell aktiver Autoantikörper gegen Rezeptoren des autonomen 
Nervensystems im Serum von CRPS Patienten weist auf eine pathogenetisch wichtige Rolle 
dieser Autoimmunphänomene bei CRPS hin. Somit tragen diese Ergebnisse zum Verständnis 
der Pathophysiologie des CRPS bei und weisen auf eine mögliche Wirksamkeit von 
Immuntherapien beim CRPS hin. 
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